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Various toxic substances may be 
present in food, but fetal exposure 
to food contaminants is poorly 
understood. This study provided new 
information about the transplacental 
transfer and metabolism of the food 
contaminants aflatoxin B1 (AFB1), 
ochratoxin A (OTA) and melamine. 
This study confirmed that these 
compounds can cross perfused 
human term placenta, at least to some 
extent. Thus exposure of a pregnant 
mother to these food contaminants 
may also lead to the exposure of 
the developing fetus. Since these 
contaminants are toxic to humans, 
exposure may pose a health risk to 
the developing fetus.
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ABSTRACT 
 
Analyses of cord blood samples have proven that human fetus can be exposed to many 
harmful compounds. Food is a significant source of contamination since it can contain 
different toxic compounds originating from the environment or formed during harvesting 
and storage or production processes and cooking. Depending on the concentration, these 
substances can pose a threat to human health. The fetus is especially susceptible to the 
effects of toxic agents because of its immature and underdeveloped defense mechanisms. 
Exposure can have detrimental effects on fetal growth and development and even increase 
the susceptibility to diseases later in life. 
Since pregnant women cannot be intentionally exposed to harmful compounds, animal 
models and other experimental methods are needed to estimate the risk of exposure to 
harmful compounds and to study related mechanisms. There are more inter-species 
differences in placental structure and function than in any other organ and therefore 
models of human origin are necessary. Placental perfusion retains the structure and 
function of term placenta for some hours and is thus a good model to investigate placental 
function.  
In this study, placental perfusion was used to investigate transplacental transfer and 
metabolism of xenobiotics. Additionally, placental tissue fractions were used to confirm the  
metabolism of xenobiotics and cell models originating from placental tissue to investigate 
the mechanisms of transfer. The following food contaminants were studied; aflatoxin B1 
(AFB1) and ochratoxin A (OTA), the naturally and widely occurring mycotoxins, and 
melamine, intentionally added to milk in China to elevate the nitrogen levels which are 
used as an indicator of protein content. 
All of the studied compounds passed through the human placenta, at least to some 
extent, but significant differences between the compounds were observed. While AFB1 and 
melamine passed easily through the placenta, transfer of OTA was minimal. Transfer of all 
studied compounds significantly differed from the transfer of the passively diffusing 
reference compound, antipyrine, indicating that mechanisms other than passive diffusion 
may contribute to the transfer. However, further studies are needed to clarify the 
mechanisms of transplacental transfer. AFB1 was metabolized to aflatoxicol in both 
perfusions and placental tissue fractions. Since AFL is as toxic as AFB1, metabolism does 
not protect fetus from the toxicity of AFB1.  
Although there are differences between the compounds, exposure of the mother to these 
toxic contaminants leads almost unavoidably to the exposure of the fetus and thus possibly 
toxicity. However, placental perfusion does not fully reflect fetal exposure: Term placentas 
were used in the perfusions but the fetus is exposed throughout the gestation. 
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TIIVISTELMÄ  
 
Napaverinäytteitä tutkimalla on saatu selville, että sikiö voi altistua haitallisille aineille. 
Ravinto on merkittävä vierasaineiden lähde. Vierasaineet voivat olla peräisin ympäristöstä 
tai niitä voi muodostua satoa kasvatettaessa ja säilytettäessä, tai tuotantoprosesseissa ja 
ruuan valmistuksessa. Riippuen konsentraatiosta nämä aineet saattavat olla haitallisia 
terveydelle. Nopeasta kasvuvauhdista ja vielä kehityksen alla olevista suojamekanismeista 
johtuen sikiö on erityisen altis vierasaineiden vaikutuksille. Sikiöaikaisella altistumisella 
voi olla haitallisia vaikutuksia sikiön kasvuun ja kehitykseen ja se voi jopa lisätä herkkyyttä 
sairauksille myöhemmin elämässä.  
Koska raskaana olevaa naista ei saa tahallisesti altistaa haitallisille vierasaineille, 
eläinmalleja ja muita kokeellisia menetelmiä tarvitaan altistumisriskin ja siihen liittyvien 
mekanismien tutkimiseen. Istukka eroaa lajien välillä enemmän kuin kuin muut elimet, 
joten ihmisen istukkaa hyödyntävät mallit ovat parhaimpia. Istukkaperfuusiossa istukan 
rakenne ja toiminta säilyvät lähes normaaleina muutaman tunnin ja se on siksi hyvä malli 
istukan toiminnan tutkimiseen.  
Tässä tutkimuksessa käytimme istukkaperfuusiota vierasaineiden istukan läpi 
kulkeutumisen ja niiden metabolian tutkimiseen. Lisäksi istukkakudosfraktioilla 
varmennettiin metaboloituminen ja istukasta peräisin olevia solulinjoja käytettiin 
kulkeutumismekanismien selvittämiseen. Ravinnon haitallisista aineista tutkittiin yleisesti 
luonnossa esiintyviä aflatoksiini B1:tä (AFB1) ja okratoksiini A:ta (OTA). Lisäksi tutkittiin 
munuaistoksista melamiinia, jota on Kiinassa lisätty maitoon nostamaan 
proteiinipitoisuuden määrittämisessä käytettyä typpipitoisuutta.  
Kaikki tutkittavat aineet kulkeutuivat istukan läpi ainakin jossain määrin, mutta 
aineiden välillä oli merkittäviä eroja kulkeutumisessa. AFB1 ja melamiini kulkeutuivat 
istukan läpi melko helposti, mutta OTA:n kulkeutuminen istukan läpi oli vähäistä. 
Kulkeutuminen istukan läpi erosi myös merkittävästi passiivisesti istukan läpi kulkeutuvan 
kontrolliaineena käytetyn antipyriinin kulkeutumisesta. Tämä viittaa siihen, että muut 
mekanismit kuin passiivinen diffuusio vaikuttavat näiden aineiden kulkeutumiseen. 
Kulkeutumismekanismien selvittäminen vaatii kuitenkin vielä jatkotutkimuksia. AFB1 
metaboloitui sekä perfuusiossa että istukan kudosfraktioissa aflatoksikoliksi. Aflatoksikoli 
on yhtä toksinen kuin AFB1, joten sen muodostuminen ei suojaa sikiötä AFB1:n 
toksisuudelta.  
Vaikka aineiden välillä on eroa, äidin altistuminen näille toksisille aineille johtaa lähes 
vääjäämättä myös sikiön altistumiseen ja mahdollisiin haittavaikutuksiin. Istukkaperfuusio 
ei kuitenkaan anna täydellistä kuvaa sikiön altistumista, koska menetelmässä käytetään 
raskauden loppuvaiheen istukkaa ja altistumista tapahtuu koko raskauden ajan. 
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Yleinen Suomalainen asiasanasto: istukka; sikiö; läpäisevyys; altistuminen; verenkierto; aineenvaihdunta; 
soluviljely; haitalliset aineet; vierasaineet; ruoka; elintarvikkeet; aflatoksiinit; okratoksiinit; melamiini 
 
VIII 
 
 
 
 
IX 
 
 
Acknowledgements 
This work was carried out in the School of Pharmacy, University of Eastern Finland (UEF), 
Kuopio and in the School of Biological Sciences, University of Hong Kong (HKU), Hong 
Kong. 
 
I wish to express my gratitude to my principal supervisor Professor Kirsi Vähäkangas for 
giving me the opportunity to work in her research group. Your enthusiasm and wide 
knowledge about science were motivating and your constructive comments and advice 
about my work, the manuscripts and thesis have been educational for me.  
 
I am grateful to my supervisor Hani El Nezami for providing me with the possibility to 
undertake part of my studies abroad. Despite the numerous tasks, your door was always 
open and you had time for discussion. Thank you for your guidance and constructive 
comments about my work, neverending optimism and ability to see the positive sides of the 
challenges that appeared during these years.  
 
I wish to offer big thanks to my supervisor Päivi Myllynen. Your excellent knowledge 
about the placenta and many laboratory techniques has helped so much in this project. 
Despite my numerous questions, you always answered quickly and patiently and gave 
very constructive and encouraging comments about manuscripts and thesis. 
 
I wish to thank Professor Kai Savolainen and Emerita Professor Hanna Tähti, official 
reviewers of my thesis, for their valuable comments and pre-examination of my thesis. I am 
honored to have Professor Luana Ricci Paulesu from the University of Siena, Italy, as an 
opponent of my thesis. I am also grateful to Dr Ewen MacDonald for the revising language 
of the thesis. 
 
I wish to express my special thanks to Chit Shing Jackson Woo for your good cooperation. 
Without your help I would be still doing experiments. I also want to thank former and 
present members of the perfusion group in Kuopio. Kirsi, Vesa and Jenni thank you for 
teaching and helping me with numerous questions and tasks when carrying out the human 
placental perfusions. Thanks also to other group members. Many thanks also to Elina and 
Maria for your collaboration and help during my visits in Oulu.   
 
I had also pleasure to supervise several BSc/MSc projects during these years. Heather, 
Kaisa, Cecilia, Soda, Carmen, Ivan and Antti thank you for your help with the laboratory 
experiments and participation in this project. Thanks also to all of the co-authors, if not 
already mentioned above, for their scientific contributions. I also want to thank the mothers 
donating their placentas for this study and the staff of the maternity ward in Kuopio 
University hospital. 
 
I also wish to thank, the personnel of the unit of Pharmacology and Toxicology, UEF, 
especially Niina, Jaana, Jenni and Hanna with whom I shared office as well as Murphy, 
Shirley and Adrian from the lab of Food Safety and Toxicology, HKU, for creating such a 
friendly working environment. 
 
 
 
X 
 
 
Many thanks also to my friends in Finland and Hong Kong for the moments we shared 
together during these years. The journeys we made together, hiking trips and yoga lessons, 
dinners and discussions were very relaxing and an important counterbalance to the 
scientific work.  
 
I also want to thank my sisters and their families for their support and for sharing the joys 
and sorrows of life. I wish to express my gratitude to my parents for their support and 
encouragement to study and reach my goals. Big thanks and hugs belong also to Kai of all 
his support, especially in the final part of the studies. 
 
This study was financially supported by the University of Eastern Finland, University of 
Hong Kong, NewGeneris, ReProTect, Food and Health Bureau of The Government of the 
Hong Kong Special Administrative Region, Finnish Graduate School of Toxicology, Finnish 
Cultural Foundation and Emil Aaltonen Foundation. 
 
 
 
Kuopio, April 2012  
 
 
 
 
Heidi Partanen  
XI 
 
 
List of the original publications 
 
This dissertation is based on the following original publications:  
 
 
I Partanen HA, El-Nezami HS, Leppänen JM, Myllynen PK, Woodhouse HJ, 
Vähäkangas KH. Aflatoxin B1 transfer and metabolism in human placenta. 
Toxicol Sci 113(1):216-225, 2010 
 
II Woo CSJ*, Partanen H*, Myllynen , Vähäkangas K, El Nezami H. Fate of the 
teratogenic and carcinogenic ochratoxin A in human perfused placenta. Toxicol 
Lett 208(1):92-99, 2012 *equal contribution 
 
III Partanen H, Vähäkangas K, Woo CSJ, Auriola S, Veid J, Chen Y, Myllynen P, El 
Nezami H. Transplacental transfer of melamine. Placenta 33(1):60-66, 2012 
 
IV Partanen H, Woo CSJ, Vähäkangas K, Myllynen P, Yip KY, Ahokas J, El Nezami 
H. The role of ABCG2 transporter in the accumulation of mycotoxins in BeWo 
cells. Submitted. 
 
 
 
 
The publications were adapted with the permission of the copyright owners. 
 
 
 
 
 
 
 
 
XII 
 
 
 
XIII 
 
 
Contents 
 
1 INTRODUCTION 1 
2 REVIEW OF LITERATURE 2 
2.1 Food contaminants ................................................................................................................... 2 
2.1.1 Toxic agents in food ........................................................................................................ 2 
2.1.2 Aflatoxins .......................................................................................................................... 5 
2.1.3 Ochratoxins ....................................................................................................................... 8 
2.1.4 Melamine ........................................................................................................................ 12 
2.2 Methods to study fetal exposure and related mechanisms .............................................. 15 
2.2.1 Epidemiological studies ................................................................................................ 15 
2.2.2 In vivo animal studies .................................................................................................... 17 
2.2.3 Ex vivo placental perfusion studies ............................................................................. 17 
2.2.4 In vitro studies ................................................................................................................ 20 
2.3 Placenta: Structure and function in relation to the scope of the thesis ........................... 21 
2.3.1 Placental structure ......................................................................................................... 21 
2.3.2 Functions ......................................................................................................................... 23 
2.3.3 Placental xenobiotic metabolism ................................................................................. 23 
2.3.4 Transfer mechanisms .................................................................................................... 24 
2.3.5 Placental transporters.................................................................................................... 25 
3 AIMS OF THE STUDY 28 
4 MATERIALS AND METHODS 29 
4.1 Ex vivo human placental perfusion method (I, II, III) ....................................................... 29 
4.1.1 Ethical aspects ................................................................................................................ 29 
4.1.2 Preparation of tissue and perfusion (I, II, III) ............................................................ 29 
4.1.3 Criteria for successful perfusion .................................................................................. 32 
4.2 Cellular fractions of human placenta for metabolism studies (I, III) .............................. 32 
4.3 Cell cultures ............................................................................................................................ 32 
4.3.1 BeWo cells (III, IV) ......................................................................................................... 32 
4.3.2 MDCK cells (III, IV) ....................................................................................................... 32 
4.3.3 MTT assay for cell viability (III) .................................................................................. 32 
4.4 Cell culture methods for characterization of transporters ............................................... 33 
4.4.1 Accumulation assay (III, IV) ........................................................................................ 33 
4.4.2 Inhibition assay (IV) ...................................................................................................... 33 
4.4.3 Transwell experiments (II) ........................................................................................... 33 
4.4.4 Transporter expression in cell lines (IV) .................................................................... 33 
4.5 Analysis of samples ................................................................................................................ 34 
4.5.1 HPLC (I, II, III, IV) ......................................................................................................... 34 
4.5.2 LC-MS (III) ...................................................................................................................... 34 
4.5.3 Scintillation counting (I, II) ........................................................................................... 34 
4.5.4 Histological evaluation of perfused placental tissue (I, II, III) ................................ 34 
4.6 Statistical analysis ................................................................................................................... 34 
 
XIV 
 
 
5 RESULTS 36 
5.1 Transplacental transfer of Aflatoxin B1, Ochratoxin A and melamine (I, II, III) .......... 36 
5.2 Placental metabolism of Aflatoxin B1 and Ochratoxin A (I, II) ....................................... 38 
5.3 Role of transporters in the transplacental transfer of mycotoxins and melamine  
      (III, IV) ...................................................................................................................................... 39 
6 DISCUSSION 41 
6.1 Transplacental transfer of Aflatoxin B1, Ochratoxin A and melamine (I, II, III) .......... 41 
6.1.1 Transfer of food contaminants through the perfused human placenta ................. 41 
6.1.2 Challenges of perfusions .............................................................................................. 43 
6.2 Metabolism of mycotoxins in human placenta .................................................................. 45 
6.3 Role of transporters in the transfer of food contaminants ............................................... 45 
6.4 Future prospectives ................................................................................................................ 47 
7 SUMMARY AND CONCLUSIONS 48 
REFERENCES 50 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XV 
 
 
Abbreviations 
 
ABCB1 ATP-binding cassette sub-
family B member 1 (MDR1, 
multidrug resistance protein 
1) (p-glycoprotein) 
ABCC1  ATP-binding cassette sub-
family C member 1 (MRP1, 
multidrug resistance-
associated protein 1) 
ABCC3  ATP-binding cassette sub-
family C member 3 (MRP3, 
multidrug resistance-
associated protein 3) 
ABCC5  ATP-binding cassette sub-
family C member 5 (MRP5, 
multidrug resistance-
associated protein 5) 
ABCG2 ATP-binding cassette sub-
family G member 2 (BCRP, 
breast cancer resistance 
protein) 
AFB1 Aflatoxin B1  
AFL Aflatoxicol 
AFM1 Aflatoxin M1 
AFQ1 Aflatoxin Q1 
CYA Cyanuric acid 
CYP450 Cytochrome P450  
DDE Dichloro diphenyl 
dichloroethylene  
DDT Dichlorodiphenyl 
dichloroethene 
DON Deoxynivalenol 
FTC Fumitremorgin C 
IARC International Agency for 
Research on Cancer 
IQ 2-amino-3-ethylimidazo[4,5-
f]quinoline 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
hCG  Human chorionic 
gonadotropin  
HCV  Hepatitis C virus 
hPL Human placental lactogen  
HPLC High performance liquid 
chromatography 
LC-MS Liquid chromatography–mass 
spectrometry 
LD50 Lethal dose 50% 
NDMA N-Nitrosodimethylamine 
OP-OTA Lactone-opening ochratoxin 
A 
OTA Ochratoxin A  
OTB Ochratoxin B 
OTα Ochratoxin α 
OTβ Ochratoxin β 
OTQH Hydroquinone metabolite of 
ochratoxin A 
XVI 
 
 
OCPs Organochlorine pesticides 
PCBs Polychlorinated biphenyls  
PCDDs Polychlorinated dibenzodioxins 
PCDD Polyclorinated dibenzo-p-dioxin 
PCDF Polychlorinated dibenzofuran 
PhIP 2-amino-1-methyl-6-
henylimidazo[4,5-b]pyridine 
PAH  Polycyclic aromatic 
hydrocarbon 
PGH  Placental growth hormone 
PLAP Placental alkaline 
phosphatase  
TDI Tolerable daily intake  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 Introduction 
Every day people are exposed to a wide variety of compounds, originating from food, 
drugs or from environmental sources. Since food is consumed daily it may be a significant 
source of contamination. It is impossible to avoid totally exposure to harmful contaminants. 
Various substances may be present in certain foodstuffs due to environmental 
contamination, cultivation practices or production processes and depending on the 
concentration, these substances can pose a threat to human health. Pregnant women are 
regarded as a particularly vulnerable group because of their own physiological state and 
because of the fetus in the womb. Rapid development, immaturity and underdeveloped 
defense mechanisms make the fetus especially susceptible to the effects of toxins (for 
reviews see Perera et al., 2002;  Neri et al., 2006;  Godschalk and Kleinjans, 2008).  
In addition to genetic factors, fetal and childhood environment including the nutritional 
status and xenobiotic exposure of the pregnant mother and fetus are considered to be 
critical for growth and lifelong disease risk (Godschalk and Kleinjans, 2008). There are 
strong indications for a link between growth and health of fetus and infant, and risk of 
several diseases later in life (Wild and Kleinjans, 2003;  Barker, 2004;  Gluckman et al., 2008). 
An increasing incidence of immunological disorders and childhood cancer in general and 
especially leukemia and central nervous system tumors have been observed during the last 
decades (Dreifaldt et al., 2004;  Dalmasso et al., 2005;  Pallapies, 2006;  Ward et al., 2006).  
For fetal risk assessment it is important to learn more about the human transplacental 
transfer of toxic compounds. Studies with human placenta are crucial because of the 
differences in the anatomy and physiology of the placenta between different species (Leiser 
and Kaufmann, 1994;  Faber, 1995;  Benirschke et al., 2006). There is evidence from animal 
and human studies demostrating that in utero exposure can induce toxic effects, including 
cancer later in the life (Anderson et al., 2000;  Miller, 2004;  Eden, 2010). While the only one 
proven transplacental chemical carcinogen in humans is diethylstilbestrol, many more are 
suspected (Anderson, et al., 2000).  
 The placenta is the primary route for fetal exposure. It contains transporter proteins 
which can facilitate or hinder the transfer of endogenous and exogenous compounds in 
both the maternal and fetal directions depending on the localization and function of the 
transporter (Vähäkangas and Myllynen, 2009). The placenta is also known to express 
metabolic enzymes which can convert xenobiotics into more easily secreted and less toxic 
forms, but which can also activate xenobiotics into more reactive and toxic metabolites 
(Pasanen and Pelkonen, 1994;  Myllynen et al., 2007). Since placenta provides nutrients and 
oxygen for the developing fetus as well as producing hormones essential for fetal growth 
and the maintenance of pregnancy, a well-functioning placenta is a prerequisite for fetal 
growth and well-being. Thus, any contaminants damaging placenta, may also be harmful 
for the fetus. The focus of this thesis is in transplacental transfer, placental metabolism and 
related mechanisms of three food contaminants; aflatoxin B1 (AFB1), ochratoxin A (OTA) 
and melamine. The selection of these toxins was based on their widespread occurrence in 
the environment, recent incidences of adverse health effects, and potentially harmful effects 
to the developing fetus. Since AFB1 and OTA occur naturally in the food and melamine 
was intentionally added into food, pregnant mothers may be exposed to these food 
contaminants through their daily diet. The human ex vivo placental perfusion method (see 
eg. Vähäkangas and Myllynen, 2006) was applied and its suitability for these studies of 
transplacental transfer of food toxins was further evaluated. 
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2 Review of Literature  
2.1 FOOD CONTAMINANTS 
2.1.1 Toxic agents in food 
Several food catastrophes, such as aflatoxin poisoning in Kenya in 2004 (Probst et al., 2007) 
and melamine tainted milk powder in China in 2008 (WHO, 2009) have shown that the 
safety of food can be threatened by contaminants. Food contaminants of natural origin are 
formed during production, harvesting or processing of food or food ingredients. Chemicals 
produced by industry, like heavy metals or pesticides, can be transferred into the food 
chain from the environment. Contaminants can also leach from packaging or storage 
containers. For financial reasons, in some cases harmful chemicals such as melamine have 
been added intentionally to food.  
Toxins produced by fungi are called mycotoxins (Table 1) (Bennett and Klich, 2003;  Wild 
and Gong, 2010). These metabolic products of fungi can contaminate a wide variety of 
crops, including cereals, nuts, spices and fruits and in some cases also meat, milk and wine. 
Mycotoxins can be found all over the world and it has been estimated that 25 % of the 
world’s cereals are contaminated by mycotoxins. Mycotoxins are both acutely toxic and 
with chronic exposure they exert teratogenic, immunotoxic and carcinogenic effects (IARC, 
1993;  IARC, 2002). The exposure and levels of the mycotoxin contamination vary 
depending on the geographical area.  
A variety of toxins are also produced by algae and dinoflagellates (Borchers et al., 2010). 
These toxins are taken up by mussels, oysters, crabs and other aquatic species and in that 
way enter the human food chain. Many of the dinoflagellate toxins are neurotoxins and 
symptoms of the poisoning appear acutely after exposure (Table 2). In experimental 
animals there are also some indications of carcinogenicity after chronic exposure to some 
marine toxins (azaspiracid) (Ito et al., 2002;  Furey et al., 2010) 
Due to increased industrial activities, exposure to toxic metals like lead, cadmium, 
mercury and arsenic, has increased (Borchers, et al., 2010;  Kantiani et al., 2010). These 
metals are persistent in the environment and accumulate in the food chain. Both acute and 
long term exposure cause adverse health effects. In addition to the metals, organochloride 
compounds [e.g. dichlorodiphenyl dichloroethene, (DDT), dibenzodioxins (PCDDs)], are 
released into the environment from industry or are used as pesticides (Kantiani, et al., 2010). 
Many of these compounds were banned many years ago but due to their lipophilicity they 
are persistent in environment and still present in food chain. Another group of pesticides, 
organophosphates, is also commonly used in agriculture. While inhalation is major route of 
exposure for farmers, food is the major source for other individuals. Many of the chemicals 
mentioned above have neurotoxic and carcinogenic effects (Table 2).  
In addition to the contamination of food from environmental sources, a variety of 
chemicals are formed during the processing and cooking of food (Borchers, et al., 2010). 
These include polycyclic aromatic hydrocarbons (e.g. benzo(a)pyrene) which are formed 
during the incomplete combustion of organic material and are found in smoked and grilled 
food. Additionally, nitroso compounds such as acrylamide, are formed when food is fried, 
deep fried or baked at a high temperature (>140°C). Contaminants can also be released 
from packing materials. For example, phthalates and bisphenol A, which are used to 
produce plastics, can be detected in food and drinks packaged in plastic containers (Table 
3 
 
 
2). Both of these chemicals are endocrine disruptors and can have detrimental effects on the 
developing fetus. 
 
 
Table 1. Main groups of mycotoxins and examples of mycotoxins from each group 
 
Mycotoxins Fungi Contaminated food Toxic effects 
Aflatoxins  
(Aflatoxin B1, G1, B2, G2) 
Species of 
Aspergillus and 
Penicillium 
Peanuts, maize, ground 
nuts 
Mutagenic, carcinogenic, 
hepatotoxic, teratogenic, 
immunotoxic. 
Ochratoxins  
(Ochratoxin A) 
Species of 
Aspergillus and 
Penicillium 
Cereals, oil seed, coffee 
beans, pulses, wine, 
poultry meat 
Nephrotoxic, hepatotoxic, 
teratogenic, immunotoxic. 
Trichothecenes  
(Deoxynivalenol , 
Nivalenol, T-2, HT-2) 
 
Species of Fusarium, 
Myrothecium, 
Phomopsis, 
Stachybotrys, 
Trichoderma, 
Trichothecium  
Cereals and cereal 
products,  maize 
Gastrointestinal 
hemorrhage and vomiting.  
Inhibit protein synthesis. 
Immunotoxic. 
 
Zearalenone Species of Fusarium Maize, wheat, barley, 
sorghum, cereal grains, 
soybeans 
Estrogenic effects. 
Fumonisins  
(Fumonisin B1, B2 and B3) 
Species of Fusarium Maize, maize products, 
sorghum, rice, cereal 
grains 
Associated with the 
occurrence of neural tube 
defect. 
Brain softening in horse. 
Zitrinin Species of 
Penicillium, 
Aspergillus and 
Monascus  
Wheat, oats, rye, 
maize, barley, rice 
Nephrotoxic. 
Patulin Species of 
Penicillium, 
Aspergillus and 
Byssochlamys 
Many fruits, grains, 
highest concentrations 
in apples and apple 
juice 
Gastrointestinal symptoms. 
Genotoxic. 
Ergot alkaloids Species of Claviseps Grains Ergotism: Gangrene, 
central nervous system 
and gastrointestinal effects 
Source of the data: (Bennett and Klich, 2003;  Richard, 2007;  Brase et al., 2009). 
 
 
Unfortunately, harmful substances have also been intentionally added to food. The most 
recent example is melamine (Table 2) which was intentionally added to milk powder to 
give a false impression of high protein concentrations. Melamine came to the attention of 
the worldwide public audience in 2008, when increased incidences of kidney stones and 
kidney failure among infants were reported in multiple regions of China following the 
consumption of melamine tainted infant milk (Hau et al., 2009;  WHO, 2009;  Skinner et al., 
2010).  
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Table 2. Examples of common food contaminants originating from sea, industrial sources or 
food processing 
 
Contaminant Source of 
contamination 
Contaminated food Toxicity 
Fish and shellfish toxins   
Saxitoxins 
Brevetoxins  
Okadaic acid 
Domoic acids 
Planktonic algae 
(dinoflagellates) 
Shellfish Paralytic, neurotoxic, 
diarrheic or amnesic shellfish 
poisoning  
Azaspiracid Planktonic algae 
(dinoflagellates) 
Shellfish Nausea, vomiting, severe 
diarrhea. Neurotoxic 
symptoms. 
Ciguatoxins 
Maitotoxins 
Planktonic algae 
(dinoflagellates) 
Coral reef fishes Gastrointestinal, 
neurological, cardiovascular 
and general symptoms. Can 
be fatal. 
Tetrodotoxin Pufferfish Improperly prepared 
meat of pufferfish 
Paralysis. Fatal. 
Heavy metals    
Lead Lead paint, water, soil  Meat, milk, fish Neurotoxic 
Mercury Environment, burning 
of coal, mining, 
cement production, 
metal processing 
Fish Neurotoxic, immunotoxic 
Cadmium Mining, industry Fish, shellfish Carcinogenic 
Arsenic Environment, industry Water Acute toxicity: nausea, 
psychosis, seizures, death. 
Skin diseases, neurological 
effects. 
Organochlorine compounds   
DDT, DDE Pesticides (banned) Accumulate in food 
chain. Foods 
containing animal fat: 
meat, milk, fish 
Probably carcinogenic to 
human 
PCDDs (e.g. TCDD), 
PCDFs,  PCBs 
Industry Accumulate in food 
chain. Foods 
containing animal fat: 
meat, milk, fish 
Carcinogenic (TCDD), 
possibly neurotoxic, disturb 
hormonal homeostasis  
Organophosphates Pesticides Contaminated food, 
water 
Neurotoxic 
Chemicals from food prosessing   
PAH compounds    
(Benzo(a)pyrene) 
Formed during the 
incomplete burning of 
organic material 
Smoked or grilled 
food 
Carcinogenic  
Amines 
(Acrylamide) 
Formed when food is 
fried, deep-fried or 
baked at high 
temperatures 
(>140°C) 
French fries, potato 
chips, cereals, bread, 
cookies 
Probably carcinogenic 
Heterocyclic amines  
(PhIP) 
Formed when heating 
protein rich food 
(meat, fish) at high 
temperatures 
Meat, fish Possibly carcinogenic 
Nitrosoamides 
(NDMA) 
Formed in a reaction 
of nitrates and amines 
Meats or fish cured 
with sodium nitrite or 
nitrate 
Probably carcinogenic 
      Continued 
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Table 2. Examples of common food contaminants originating from sea, industrial sources or 
food processing, Continued. 
 
Contaminant Source of 
contamination 
Contaminated food Toxicity 
Chemicals from packing material   
Phthalates Plastic and PCV 
products 
Fatty foods, dairy 
products, meat, fish, 
oils 
Reproductive toxicity in 
experimental animals, 
probably also humans 
Bisphenol A Plastic bottles and 
storage boxes 
Food stored in plastic 
containers  
Endocrine disruptor 
Others  
Melamine 
 
Plastics, coatings, 
glues and tableware. 
Tainted milk powder. 
 
Milk powder, infant 
milk,  ice cream, 
cookies 
 
Nephrotoxic, damage kidney 
tubules when stones are 
formed 
 
2.1.2 Aflatoxins 
 
Exposure to aflatoxins 
Aflatoxins are fungal toxins produced by a species of Aspergillus moulds, mainly by 
Aspergillus flavus and Aspergillus paraciticus (IARC, 2002;  Williams et al., 2004). Aflatoxin B1 
(AFB1), AFB2, AFG1 and AFG2 are the four main naturally occurring aflatoxins but several 
derivates [e.g. AFM1, AFQ1, aflatoxicol (AFL)] have also been identified. Because of their 
strong fluorescence, aflatoxins are named according to the color of the light emitted, B for 
blue and G for green color. AFB1 is the most prevalent and most toxic of the natural 
aflatoxins. AFB1 accounts for 75% of all aflatoxins found in contaminated food and feeds 
(Ayub and Sachan, 1997). 
Aflatoxins are common food contaminants found all over the world, although mostly in 
regions where hot and humid climates favor the growth of these fungi and where food is 
improperly stored (Williams, et al., 2004). The moulds producing aflatoxins are able to 
contaminate a variety of agricultural commodities, but the most pronounced contamination 
is encountered in maize, peanuts, cottonseed and tree nuts (IARC, 2002). AFM1 has also 
been detected in milk and meat (Stubblefield et al., 1983). People are exposed to aflatoxins 
mainly through contaminated food, but occupational exposure occurs as well. Workers in 
factories processing animal food and in farms handling maize and rice can be exposed to 
the dust containing aflatoxins (Autrup et al., 1993;  Ghosh et al., 1997;  Nuntharatanapong et 
al., 2001;  Desai and Ghosh, 2003).  
Since aflatoxins are common food contaminants, also pregnant mothers are exposed to 
these agents, which may lead to the exposure of developing fetus. Several lines of evidence 
point to a significant exposure to AFB1 both in the prenatal and postnatal stages. Several 
studies have reported high levels of aflatoxins in maternal and cord blood of mothers living 
in contaminated areas, which proves that aflatoxins can cross human placenta (De Vries et 
al., 1989;  Denning et al., 1990;  Hsieh and Hsieh, 1993b;  Abdulrazzaq et al., 2002). 
Additionally, aflatoxin-albumin (AF-alb) adducts have been detected in both maternal and 
cord blood (Wild et al., 1991;  Hsieh and Hsieh, 1993a;  Turner et al., 2007). In infants and 
young children, AF-alb adducts have been found in blood (Gong et al., 2004;  Turner, et al., 
2007) with aflatoxins being present in urine (Polychronaki et al., 2008). Additionally, AFM1 
has been detected in breast milk (Galvano et al., 2008). 
Aflatoxin exposure levels vary considerably depending on the geographical region. In 
the developed countries there are rather low estimated exposures [e.g. in European Union 
(0.35-1.93 ng aflatoxins/kg body weight/day) (EFSA, 2007), Japan (0.003–0.014 ng 
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aflatoxins/kg body weight/day) (Sugita-Konishi et al., 2010) and Australia (0.15 ng 
aflatoxins/kg body weight/day for adults and up to approximately 0.45 ng aflatoxins/kg 
body weight/day for children) (IARC, 2002)] due to the efficient control of imported food 
products. However, in regions with favorable climates for the growth of molds, as in Sub-
Saharan Africa and South-East Asia, exposure levels can be high. In China, the estimated 
intake of AFB1 ranges from 0 to 91 μg/kg body weight per day (IARC, 2002;  Sun et al., 
2011). 
Aflatoxin limits in food and food products intended for human use vary from 4 to 30 μg 
total aflatoxins / kg food depending on the country (Williams, et al., 2004). The strictest 
regulations are in the European Union countries, but there are countries with even no 
regulations to limit the amount of aflatoxins in food. The maximum limits set by European 
Commission for nuts, fried fruits, cereals and processed foods for human consumption are 
2 μg/kg for AFB1 and 4 μg/kg for total aflatoxins (AFB1 + B2 + G1 + G2) and the limit for 
AFM1 in milk and milk products is 0.05 μg/kg (EC, 2006). Even stricter limits are placed on 
for food intended for consumption by infants and young children, the maximum limit for 
processed cereal based foods and baby foods being 0.1 μg AFB1/kg foods and 0.025 μg 
AFM1/kg foods (EC, 2006). In China, the maximum limits for AFB1 are 20 μg/kg maize and 
maize products and for AFM1 0.5 μg/kg milk and milk products (FAO, 2004). 
 
Toxicity of aflatoxins 
Aflatoxins are both acutely and chronically toxic. Exposure to high levels of aflatoxins can 
lead to acute poisoning, aflatoxicosis, characterized by hemorrhagic necrosis of liver, bile 
duct proliferation, edema and lethargy, and ultimately the condition can be lethal 
(Williams, et al., 2004). There have been several acute mass poisonings by aflatoxins in the 
countries of Africa and Asia (Krishnamachari et al., 1975;  Lewis et al., 2005;  Probst, et al., 
2007;  Kensler et al., 2011). The most recent severe outbreak of aflatoxicosis, resulting in 317 
cases and 125 deaths, occurred in Kenya in 2004 (Probst, et al., 2007). The major source of 
the contamination was aflatoxin contaminated maize grown and eaten in family farms in 
rural areas of Kenya. The contamination levels of maize were far above the regulatory 
limits (20ppb equal to 20 μg/kg) (Lewis, et al., 2005). When samples were collected from the 
affected areas, it was found that 55% were contaminated with aflatoxins and in 35% the 
contamination levels were >100 ppm (100 mg/kg) and in 7 % of samples >1000 ppm (1000 
mg/kg) (Lewis, et al., 2005). 
Animal experiments have revealed that aflatoxins are mutagenic, carcinogenic, 
teratogenic and immunotoxic (IARC, 2002). The main effect seen after chronic exposure to 
AFB1 is hepatocellular carcinoma (HCC). Simultaneous exposure to both AFB1 and 
hepatitis B (HBV) and/or C viruses (HCV) synergistically increases the risks of HCC (for 
reviews see Williams, et al., 2004;  Wild and Montesano, 2009). The AGG → AGT point 
mutation in codon 249 on the TP53 tumor suppressor gene is typically detected in tumors 
of HCC patients with HBV in the areas of high exposure to aflatoxins (Wild and Turner, 
2002;  Turner et al., 2003;  Wild and Montesano, 2009). The higher prevalence and 
occurrence of HCC at earlier ages in the areas of high exposure to aflatoxins also indicate 
that AFB1 has a significant role in the development of HCC (IARC, 2003). The International 
Agency for Research on Cancer (IARC) has classified AFB1 as a group 1 carcinogen 
(carcinogenic to human). In addition to HCC, aflatoxins induce kidney tumors in 
experimental animals (IARC, 2002). There are also a few studies indicating that exposure to 
aflatoxins can modulate immune functions in humans. In Gambian children, the presence 
of AF-alb adducts in blood has been associated with reduced IgA levels (Turner, et al., 
2003). A decrease of blood levels of lymphocyte markers (Jiang et al., 2005) as well as 
alterations in lymphocytes (Jiang et al., 2008) were reported to correlate with high AF-alb 
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adduct levels indicating that exposure to aflatoxins may have reduced host resistance to 
infections. Exposure of infants and children to aflatoxins was associated with growth 
impairment (Gong et al., 2002;  Gong, et al., 2004;  Turner, et al., 2007). Aflatoxin exposure 
has been also associated with delayed recovery from malnutrition (IARC, 2002;  Williams, et 
al., 2004). 
 
Metabolism of aflatoxins 
In order to elicit its toxic properties, AFB1 requires metabolic activation (Figure 1). AFB1 is 
metabolized mainly in the liver by cytochrome P450 (CYP450) enzymes i.e. CYP3A4, 1A2, 
3A5 and 3A7 are involved in its metabolism (Kamdem et al., 2006). The individual 
contribution of these CYP enzymes in AFB1 metabolism depends on the affinity and 
variations in the expression levels in individuals (Kamdem, et al., 2006). CYP3A4 is the 
main enzyme responsible for the formation of the highly reactive AFB1-8,9-epoxide. Both 
AFB1-8,9-endo-epoxide and AFB1-8,9-exo-epoxide are formed, but only AFB1-8,9-exo-
epoxide is genotoxic. It binds to DNA to form predominantly the 8,9-dihydro-8-(N7-
guanyl)-9-hydroxy AFB1 (AFB1-N7-Gua) adduct which may lead to the growth of the 
tumor (Guengerich et al., 1998;  Kamdem, et al., 2006). CYP3A5 also plays an important role 
in the formation of epoxide in some individuals (Kamdem, et al., 2006). In human fetus, 
CYP3A7, a major CYP in human fetal liver, has the capacity to activate AFB1 to its 8,9-
epoxide (Kamdem, et al., 2006). It has also been reported that lipoxygenase in human term 
placenta, and in the intrauterine conceptual tissue (including placenta) at 8–10 weeks of 
gestation, is capable of epoxidation of AFB1 (Datta and Kulkarni, 1994). An increase of 
mutagenic activity of AFB1 in Salmonella typhimurium TA100 by incubation with placental 
microsomal protein is another indication of the capacity of placental tissue to activate AFB1 
(Sawada et al., 1993).  
CYP3A4 and 1A2 can also oxidize AFB1 to various other metabolites than epoxides. The 
hydroxylated metabolite, aflatoxin M1 (AFM1), is mainly formed by CYP1A2 and is 
excreted into urine and milk. The other common metabolite aflatoxin Q1 (AFQ1) is mainly 
produced by CYP3A5 (Guengerich, et al., 1998). AFB1 can also be metabolized by a 
NADPH-dependent reductase into a carcinogenic metabolite, aflatoxicol (AFL) (Wong and 
Hsieh, 1976;  Salhab and Edwards, 1977). AFL acts as a reservoir of AFB1, prolonging its 
lifetime in the body, as it can be reconverted enzymatically to AFB1, which then can be 
further metabolized to other metabolites. The formation of AFL does not decrease the 
toxicity of AFB1 because this metabolite can also bind to DNA and it is as potent a 
carcinogen as AFB1 (Bailey et al., 1994;  Bailey et al., 1998). Additionally, AFB1 metabolites 
can be further conjugated with glutathione (GSH), sulphate or glucuronide and then 
excreted to urine and feces (Guengerich, et al., 1998). 
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Figure 1. Aflatoxin B1 (AFB1) metabolism to its main metabolites; aflatoxin B1-8,9-epoxide 
(AFB1-8,9-epoxide), aflatoxin M1 (AFM1), aflatoxin Q1 (AFQ1) and aflatoxicol (AFL). Modified 
from (Wild and Turner, 2002). 
 
2.1.3 Ochratoxins 
 
Exposure to ochratoxins 
Ochratoxins are a group of structurally related secondary metabolites produced primarily 
by the molds Penicillium verrocosum, Aspergillus ochraceus and occasionally also by 
Aspergillus niger (Pfohl-Leszkowicz and Manderville, 2007;  Borchers, et al., 2010;  Kuiper-
Goodman et al., 2010). The most abundant and toxic mycotoxin in this group is ochratoxin 
A (OTA) which is known to contaminate a great number of foodstuffs. Cereals and cereal-
based food are the main contributors to OTA intake foods, but these contaminant  also can 
be present in dried vine fruits and wine, other dried fruits, soy and soy products, oil seeds, 
nuts and coffee beans (Kuiper-Goodman, et al., 2010).  
OTA contaminates food all over the world. The highest levels of OTA have been 
reported from Eastern Europe in plant derived food including rye flour from Poland (5410 
μg/kg) and barley from Czech Republic (3800 μg/kg) (Pfohl-Leszkowicz and Manderville, 
2007). In the area of the former Yugoslavia, 8 to 12 % of cereals have been reported to be 
contaminated with OTA (Vrabcheva et al., 2004). The maximum limits set by the European 
Commission for OTA in cereals and cereal products, and wine for human consumption are 
3 μg OTA/kg  and 2 μg OTA/kg food, respectively. Even tighter limits have been set for 
food intended for infants and young children, the maximum limit for processed cereal 
based foods and baby foods being 0.5 μg OTA/kg foods (EC, 2006). The estimated exposure 
for average European consumer range from 2 to 3 ng/kg body weight/day (EFSA, 2006). 
The presence of OTA in human blood has been reported in many countries, especially in 
Europe (Coronel et al., 2010). Exposure to OTA varies extensively depending on the area 
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(Table 3). The highest levels of OTA have been found in blood samples collected from 
Argentina (0.012 - 74.8 ng OTA/ml) and the lowest in samples from Japan (0.004 - 0.263 ng 
OTA/ml) (Coronel, et al., 2010). Regional differences in OTA levels have been observed in 
many countries, which may be explained by differences in diet or climate. Additionally, 
there is also a seasonal variation in the blood levels of OTA. In Turkey, this seasonal 
variation of OTA exposure has been quantified, mean serum levels being 0.137 ng/ml in 
winter and 0.312 ng/ml in summer (Erkekoglu et al., 2010). Serum OTA levels in pregnant 
women ranging from 0.06 to 3.41 ng/ml have been reported (Zimmerli and Dick, 1995;  
Rosner et al., 2000;  Postupolski et al., 2006). In utero exposure of human fetuses to OTA has 
been proven by the presence of OTA in fetal serum and cord blood samples at 0.13-5.42 
ng/ml (Zimmerli and Dick, 1995;  Postupolski, et al., 2006), which raises concerns about the 
potential health hazards to human fetuses. OTA is also excreted into breast milk which is a 
potential source of exposure to infants (Breitholtz-Emanuelsson et al., 1993;  Galvano, et al., 
2008;  Biasucci et al., 2011). 
 
 
Table 3. Occurrence of ochratoxin A (OTA) in human plasma in different countries 
 
Continent Country Range of concentrations 
ng OTA / ml plasma 
South America Argentina <0.012 - 74.8 
 Chile 0.07 – 2.75 
   
North America Canada 0.29 – 2.37 
   
Europe Czech Republic 0.1 – 13.7 
 Germany 0.1 – 14.4 
 Italy 0.12 – 2.84 
 Norway 0.021 – 5.534 
 Portugal 0.14 -2.49 
 Spain 0.06 – 10.92 
 Switzerland 0.06 – 6.02 
 UK 0.4 – 3.11 
 Turkey 0.028 – 1.496 
   
Asia Japan 0.004 -0.263 
 
Middle East / Africa Lebanon 0.1 – 0.87 
 Morocco 0.08 – 6.59 
 Tunisia 1.0 – 21.6 
Table combined from Coronel et al. 2010, Erkekog˘lu et al. 2010, Coronel et al. 2011, Zaied et al. 2011 
 
Toxicity of ochratoxin A 
Kidney is the primary target organ for OTA toxicity. OTA has been shown to induce 
nephropathy in many animal species such as pigs, rats, chickens and other poultry.  It is 
one of the most potent renal carcinogens known, inducing renal adenomas and carcinomas 
in rats and mice (Pfohl-Leszkowicz and Manderville, 2007). In addition to its role as a 
contributing factor in kidney tumors, OTA treatment has induced mammary gland tumors 
and liver tumors in experimental animals such as rats and mice (Clark and Snedeker, 2006). 
In humans, exposure to OTA has been suggested to be the main etiological factor in the 
development of Balkan Endemic Nephropathy. However, recent studies now favor a 
causative role of aristolochic acid over OTA (Grollman and Jelakovic, 2007). Due to the 
strong evidence for carcinogenicity in experimental animals and insufficient evidence in 
humans, International Agency for Research on Cancer (IARC) has classified OTA as 
“possibly carcinogenic to humans” (Group 2B carcinogen).   
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In addition to its nephrotoxicity and carcinogenicity, OTA is also a potent teratogen in 
mice, rats, hamsters, chickens and rabbits but not pigs (Pfohl-Leszkowicz and Manderville, 
2007). A recent study in rats indicated that exposure at gestation days 6 and 7 were the 
most critical for the OTA induced teratogenicity (Patil et al., 2006). OTA has immunotoxic 
effects in many animal species e.g. lymphopenia in dogs, chickens, turkeys and pigs, and 
thymus regression and immunosuppression in mice (Pfohl-Leszkowicz and Manderville, 
2007). 
 
Metabolism of ochratoxin A 
OTA can be biotransformed not only by animals, humans and plants, but also by fungi, 
yeast and bacteria as reviewed in an extensive recent review (Wu et al., 2011). The major 
metabolic pathways are hydrolysis, hydroxylation, lactone opening and conjugation.  Most 
of the metabolites formed are less toxic than OTA. In animals, OTA is metabolized to many 
different products (Figure 2). The non-toxic ochratoxin α (OTα) is the main metabolite, but 
hydroxylated metabolites 10-hydroxyochratoxin A (10-OH-OTA), 4-(R)- and 4-(S)-
hydroxyochratoxin A (4-(R)-OH-OTA and 4-(S)-OH-OTA), hydroquinone metabolite of 
ochratoxin A (OTHQ) as well as a toxic metabolite, a lactone-opening ochratoxin A (OP-
OTA), can be formed. Ochratoxin B (OTB), which can be further metabolized to ochratoxin 
β (OTβ), can also be formed. In comparison to animals, humans seem to have lower 
capability to metabolize OTA. Two metabolites, 4-(R)-OH-OTA) 4-(S)-OH-OTA are formed 
in human liver microsomes, with 4-(R)-OH-OTA being the major species, its formation is 
catalyzed by CYP1A1 and 3A4. OTα is also formed in human bronchial epithelial cells 
(Pinelli et al., 1999). Many micro-organisms are able to degrade OTA into non-toxic 
metabolites, this may be a reasonable way to reduce OTA toxicity in contaminated food and 
feed (Wu, et al., 2011). 
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Figure 2. Metabolism of ochratoxin A (OTA) to the main metabolites [ochratoxin β (OTβ), 
ochratoxin B (OTB), lactone-opening ochratoxin A (OP-OTA), ochratoxin α (OTα), hydroquinone 
metabolite of ochratoxin A (OTHQ), 10-hydroxyochratoxin A (10-OH-OTA), 4-(R)-
hydroxyochratoxin A (4-(R)-OH-OTA), 4-(S)-hydroxyochratoxin A (4-(S)-OH-OTA)] in human 
and animals. Modified from (Wu, et al., 2011). 
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2.1.4 Melamine 
 
Exposure to melamine 
Melamine (2,4,6-triamino-1,3,5-triazine) is a nitrogen-rich (66% nitrogen by weight) 
heterocyclic triazine with low water solubility (3.240 mg/ml) (WHO, 2008). It is widely used 
in manufacturing industries for the synthesis of plastics called melamine formaldehyde 
resins. These have a broad range of applications being incorporated into laminates, plastics, 
coatings, glues and adhesives, as well as in tableware. Melamine is also used as a colorant 
and as a fertilizer.  
In 2007, worldwide production of melamine was approximately 1.2 million tonnes, with 
the predominant producers being in China and Western Europe (WHO, 2008). Melamine 
can be produced from three different starting materials: urea, dicyandiamide or hydrogen 
cyanide, of which urea is most commonly used for the manufacture of melamine. During 
the production of melamine, by-products cyanuric acid (CYA), ammeline and ammelide 
can also be formed (Figure 3). In addition to the presence during manufacturing, melamine 
side products (CYA, ammeline and ammelide) can also be formed by bacteria (Pseudomonas 
strain A and Klebsiella terragena) during the conversion of melamine into carbon dioxide and 
ammonia (WHO, 2008). 
 
 
 
 
Figure 3. Structure of melamine and its by-products cyanuric acid, ammelide and ammeline 
(WHO 2009). 
 
Melamine and its analogues (CYA, ammeline and ammelide) may be present in the 
environment or in the food chain as a result of their illegitimate widespread use or as a 
result of the degradation of precursor compounds. Melamine has been detected at levels 
between 0.5 and 2.2 mg/kg in coffee, orange juice, fermented milk and lemon juice 
(Ishiwata et al., 1987). These levels may have originated after being dissolved into the 
beverage from cups, made of melamine-formaldehyde resin, under hot and acidic 
conditions. The pesticide, cyromazine, is partially metabolized to melamine. Both melamine 
and cyromazine can be detected in meat and egg of hens fed food treated with cyromazine 
(Meek et al., 2003). Additionally, melamine has also been detected on the surface of fruits 
and vegetable crops sprayed with cyromazine (Lim, 1990;  Patakioutas et al., 2007). Recent 
reports indicated that melamine could also be carried from animal feed into milk and milk 
products when cows have been fed with melamine contaminated animal feeds (Cruywagen 
et al., 2009;  Battaglia et al., 2010;  Shen et al., 2010) Remnants of melamine containing 
disinfectants like, trichloromelamine which decomposes to melamine, may also be detected 
in food (WHO, 2009). The background levels of melamine exposure from different sources 
are estimated to be low (Table 4) (WHO, 2009). 
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Table 4. Estimates of exposure to melamine from background sources and from adulterated 
infant milk 
 
Category Estimated daily exposure* 
(μg/kg body weight) 
Infant formula  0.54–1.6 
Infant formula after adulteration 10.4-28.61, (110.2)2 
Other foods  0.03–0.12 
Disinfection in food processing 7 
Migration from melamine containing plastics 13 
Migration from melamine containing adhesives <0.35 
Residues arising from cyromazine use 0.04–0.27 
Source: WHO (2009) Toxicological and Health Aspects of Melamine and Cyanuric Acid. Report of a WHO 
Expert Meeting In collaboration with FAO, Supported by Health Canada, Ottawa, Canada 
* Background dietary exposure is estimated based on data from 17 countries in Europe, a region where 
processed foods form a significant part of the diet. 
1estimated mean exposure, 2estimated maximum exposure 
 
Direct addition of melamine to food is not allowed. However, due to its high nitrogen 
content, melamine has been added illegally into food products to increase the nitrogen 
content of the end products. This is possible because the Kjeldahl method, an assay 
commonly used for protein analysis in the food industry, is non-specific and only measures 
the total nitrogen content in organic nitrogenous compounds but not actual proteins. Thus 
the method cannot distinguish between nitrogen from protein and from non-protein 
sources (Hau, et al., 2009). Since melamine has a high nitrogen content and it is inexpensive, 
it became an attractive fraudulent substitute for genuine protein. So far, there have been 
two outbreaks where melamine has been intentionally added into food or food products. 
 
Toxicity of melamine 
In 2007, a large number of cats and dogs suffered severe renal failure leading to the death of 
more than 1000 cats and dogs (Brown et al., 2007;  WHO, 2008). Melamine and other 
triazines were found at the levels of 0.001–0.7% in contaminated pet food. Wheat gluten 
and rice protein extract contaminated with melamine and related triazines (levels ranging 
from 0.8% to 26%) have been imported from China and was used to manufacture pet food 
in the North America. A similar kind of outbreak was also seen in 2004 when cats and dogs 
suffered severe renal failure in several Asian countries. Subsequent analysis revealed that 
the acute renal failures suffered by animals from both pet food incidents were associated 
with the presence of melamine and cyanuric acid (Brown, et al., 2007;  Thompson et al., 
2008). 
In 2008, increased incidences of kidney stones and kidney failure among infants were 
reported in many regions of China. Almost 300 000 infants and young children were 
affected, at least 52 000 were hospitalized and 6 infants even died after consumption of 
melamine contaminated infant milk. Infants and young children suffered severe renal 
failure, characterized by the formation of calculi and bladder stones after exposure to 
melamine. The estimated exposure levels of melamine in infants and young children were 
much higher (up to 110.2 mg/kg body weight) than acceptable levels of melamine intake 
(TDI 0.2 mg/kg) (WHO, 2009), explaining the dramatic toxicity observed in these infants. 
Not only infant milk was found to be contaminated but also many other food products 
containing milk powder like yoghurt, ice cream, chocolate, biscuits and cakes were 
adulterated. Many of these products had also been exported throughout the world and the 
cases of melamine contamination was reported in 47 countries (Gossner et al., 2009). Since 
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urolithiasis is a condition not commonly found in children, the outbreak of urinary stones 
and renal failure in Chinese children raised worldwide concern (Lam et al., 2009). 
Melamine has low acute toxicity. The LD50 for male rats and mice is 3161 mg/kg which 
is the lowest oral LD50 in tested rodents (WHO, 2009). However, long term exposure to 
melamine evokes chronic inflammation and melamine has been found to be carcinogenic to 
experimental animals (WHO, 2009). Melamine has been shown to induce development of 
urinary bladder and urethral carcinomas in male rats and urinary bladder hyperplasia in 
male mice (IARC, 1999). The occurrence of urinary bladder tumors in male rats was shown 
to be dose dependent and correlated with calculi formation (Okumura et al., 1992;  
Ogasawara et al., 1995). There is inadequate evidence in humans for the carcinogenicity of 
melamine and melamine is categorized in class 3 (not classifiable as to its carcinogenicity to 
human) by the IARC (IARC, 1999).  
Studies with experimental animals and melamine outbreaks in pets and infants have 
shown that melamine toxicity correlates with dose and calculi formation. The formation of 
calculi is more probable at high concentrations or in the presence of by-products like 
cyanuric acid. In the pet food incident, the stones mainly consisted of melamine and 
cyanuric acid (Figure 4). In infants, the stones consisted of melamine and uric acid and size 
of the stones was strongly correlated with the exposure levels to melamine indicating, that 
melamine exposure was linked to kidney stone formation in humans (Lam, et al., 2009). The 
formation of stones that obstructed and damaged kidney tubules was presumed to be the 
main reason of renal failure in both infants and pets (WHO, 2009). Recent studies also 
indicated that melamine could modulate immune responses because leukocytoria and 
altered cellular defense functions have been reported in exposed infants (Zhou et al., 2010).  
 
 
 
 
 
 
Figure 4. Melamine –cyanuric acid complex. The blue molecule represents melamine and the red 
cyanuric acid. Modified from (WHO, 2009).  
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Melamine is not mutagenic or teratogenic (IARC, 1999), but melamine related 
compounds like triethylenemelamine (TEM) can act as mutagens and teratogens (Reddy et 
al., 1980;  Generoso et al., 1988). However, a recent study in rat has indicated that melamine 
can cross the rat placenta in a dose-dependent manner and affect renal function of the 
pregnant dams (Jingbin et al., 2010). When pregnant or lactating rats were fed with 
melamine, the compound was found in dam sera, amniotic fluid and in the fetus as well as 
in breast milk (Chu et al., 2010;  Jingbin, et al., 2010;  Chan et al., 2011). Very few publications 
exist about the effects of melamine exposure to infant and fetus. A recent study indicated 
that melamine could affect learning and memory functions of infant rat (Yang et al., 2011). 
In humans, no earlier studies in the literature on placental transfer of melamine existed. 
Since the placenta differs more than any other organ between different species (Benirschke, 
et al., 2006), it is difficult to draw any conclusions about human fetal exposure based results 
obtained from animal experiments.  
2.2 METHODS TO STUDY FETAL EXPOSURE AND RELATED MECHANISMS 
2.2.1 Epidemiological studies 
Epidemiological studies have revealed that pregnant mothers are exposed to numerous 
xenobiotics such as mycotoxins, heterocyclic amines and polycyclic aromatic hydrocarbons 
(PAHs) (Table 5) (Denning, et al., 1990;  Hsieh and Hsieh, 1993b;  Zimmerli and Dick, 1995;  
Abdulrazzaq, et al., 2002;  Perera et al., 2005a;  Postupolski, et al., 2006;  Biasucci, et al., 2011;  
Sexton et al., 2011;  von Stedingk et al., 2011). Since this probably leads to fetal exposure it is 
important to estimate in utero exposure to xenobiotics by testing biological specimens from 
the mother during gestation or measurement in cord blood or the neonate shortly after 
birth (Barr et al., 2007;  Gray and Huestis, 2007;  Arbuckle, 2010). The analysis of such 
samples provides important information about real exposure levels.  
Biological fluids and specimens such as urine, plasma, hair, oral fluid and sweat can be 
collected for exposure analysis of the mother. Exposure levels from the mother can be used 
to evaluate or estimate fetal exposures. The exposure of fetus can be also measured by 
collecting neonatal specimens such as urine, meconium, vernix caseosa (white substance 
coating the skin of newborn babies), umbilical cord blood, umbilical cord tissue, placenta, 
hair, finger and toenails shortly after birth (Gray and Huestis, 2007;  Arbuckle, 2010). The 
presence of a xenobiotic in umbilical cord blood or amniotic fluid and meconium, or in fetal 
samples is unequivocal evidence of xenobiotic transfer to the fetal compartment (Barr, et al., 
2007). Meconium, the earliest stool excreted by an infant, is one of the most sensitive 
matrices for in utero exposure because it represents compounds which have accumulated 
from the twelfth week of gestation and provides a measure of chronic exposure (Barr, et al., 
2007). Umbilical cord tissue and blood samples as well as amniotic fluid can be collected 
after delivery (Gray and Huestis, 2007). Cord blood samples reflect the recent exposure 
while amniotic fluid which acts as a fetal excretion reservoir reflects contamination taking 
place throughout the pregnancy. Hair and nail samples of fetus reflect the exposure during 
the last trimester of pregnancy.  
Evaluating fetal exposure is a complex process since it is greatly dependent on the 
properties of the xenobiotic being tested e.g  lipophilicity and binding to proteins which can 
affect the persistence and detectibility of the chemical in biological specimens (Barr, et al., 
2007). For persistent contaminants, analysis of one sample type may be sufficient to 
evaluate fetal exposure. For non-persistent contaminants, longitudinal monitoring of 
different kinds of samples collected during pregnancy as well as the analysis of fetal 
samples may be required (Barr, et al., 2007). If one wishes a comprehensive understanding 
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about transfer of xenobiotics through human placenta and the mechanisms involved, then 
both in vivo and in vitro studies are needed. 
 
 
Table 5. Food contaminants detected in cord blood or fetal biological specimens  
 
Chemical group Food contaminant Matrix measured References 
Amines Acrylamide Adducts in cord blood (von Stedingk, et al., 
2011) 
 Glycidamide Adducts in cord blood (von Stedingk, et al., 
2011) 
Metals Cadmium Cord blood, placenta (Butler Walker et al., 
2006;  Al-Saleh et al., 
2011) 
 Lead Cord blood, meconium, 
placenta 
(Butler Walker, et al., 
2006;  Gundacker et 
al., 2010;  Al-Saleh, 
et al., 2011) 
 Mercury Cord blood, meconium, 
infant’s hair, placenta 
(Ramirez et al., 2000;  
Butler Walker, et al., 
2006;  Unuvar et al., 
2007;  Gundacker, et 
al., 2010;  Al-Saleh, 
et al., 2011) 
Mycotoxins Aflatoxins Cord blood (De Vries, et al., 
1989;  Denning, et 
al., 1990;  Hsieh and 
Hsieh, 1993b;  
Jonsyn et al., 1995;  
Abdulrazzaq, et al., 
2002) 
 Ochratoxins Cord blood, fetal blood (Jonsyn, et al., 1995;  
Postupolski, et al., 
2006;  Biasucci, et 
al., 2011) 
Organochlorine 
pesticides (OCPs) 
 
Hexachlorobenzene 
(HCB), DDT etc. 
Cord blood (Whyatt et al., 2003;  
Perera, et al., 2005a;  
Jaraczewska et al., 
2006;  Tsang et al., 
2011)  
Organophosphate 
pesticides 
 
Parathion, malathion 
etc. 
Cord blood (Whyatt, et al., 2003;  
Whyatt et al., 2005) 
Polychlorinated 
biphenyls (PCBs) 
 Cord blood (Jaraczewska, et al., 
2006;  Tsang, et al., 
2011) 
Polycyclic aromatic 
hydrocarbons (PAHs) 
Benzo(a)pyrene, 
acenaphthylene, 
anthracene etc. 
Cord blood, DNA adducts 
in cord blood 
(Perera, et al., 2002;  
Perera, et al., 2005a;  
Perera et al., 2005b;  
Whyatt, et al., 2005;  
Sexton, et al., 2011;  
Tsang, et al., 2011;  
Yu et al., 2011) 
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2.2.2 In vivo animal studies 
Since humans cannot be intentionally exposed to harmful chemicals, experimental models 
are also needed to obtain more information about fetal exposure and mechanisms of 
exposure. Studies on experimental animals provide information about transplacental 
transfer and toxicity of xenobiotics and can be used as supplemental data in estimating the 
risk of human exposure. However, when extrapolating data from animal experiments to 
humans the differences between species need to be taken into account (Myren et al., 2007). 
Since inter-species in anatomy and physiology of the placenta differ more than any other 
organ (Leiser and Kaufmann, 1994;  Faber, 1995;  Benirschke, et al., 2006) models of human 
origin are most useful in evaluating human fetal exposure. However, when using animal 
models, one could argue that it would be best to select the species close to human e.g. non-
human primates (Carter, 2007). However, there are major ethical questions with the use of 
primates. Small laboratory animals such as the mouse are probably the most commonly 
used as animal models of prenatal exposure. The advantages of the mouse are its small size, 
short generation and its large litter (Carter, 2007). However, pregnancy and placental 
structure and function greatly differ from humans. While human placenta is villous and 
hemochorial in structure (Benirschke, et al., 2006), the mouse placenta is a labyrinth type 
with three cell layers separating maternal and fetal circulations. Due to the short generation 
times, small animals are useful when evaluating long term effects such as the influences of 
exposure from generation to generation and when assessing the effects of xenobiotic 
exposure to reproduction and development. Larger mammals such as sheep have been also 
used to evaluate the effects of xenobiotic exposure. Because of the their long gestation and 
ease of handling sheep are widely used to study fetal physiology (Carter, 2007). However, 
the sheep placenta is very different from the human placenta and thus a poor model to 
study transfer through the placenta. Knockout animals are also useful models for 
mechanistical studies. Even though models of human origin are valuable ways to evaluate 
human fetal exposure, animal models are important in the evaluation of toxicity and 
teratogenicity of xenobiotics (Vähäkangas and Myllynen, 2006). 
2.2.3 Ex vivo placental perfusion studies 
Placental perfusion method retains fully the structure of human placenta (Mathiesen et al., 
2010). Thus it may be one of the best methods to study placental transfer and toxicity of 
xenobiotics in humans (Vähäkangas and Myllynen, 2006). This method has been 
successfully utilized to study transplacental transfer of many xenobiotics such as many 
drugs, environmental contaminants and nowadays also an increasing amount of food 
contaminants (Table 6) have been examined with this technique.  
The perfusion method of a single cotyledon of placenta was developed in 1960s by 
Panigel and further developed by Schneider and colleagues (Schneider et al., 1972). 
Nowadays, there are several variations of this method; usually a single cotyledon of the 
term placenta is cannulated to establish separate fetal and maternal circulations. The 
perfusate can be then circulated either once through the placenta (Schneider, et al., 1972) or 
recirculated for several hours (Brandes et al., 1983). Usually placental perfusions are carried 
out for a couple of hours, but placenta has also been successfully perfused for up to 48 
hours (Polliotti et al., 1996). Placental perfusion can be used to study transplacental transfer 
of compounds in both directions; from maternal to fetal circulation or in the opposite way. 
In addition to transfer studies, perfusion can be utilized to study the role of the placental 
transporters, placental metabolism, DNA adduct formation, production and release of 
hormones and enzymes and transport of nutrients and waste products (Vähäkangas and 
Myllynen, 2006;  Myren, et al., 2007;  Myllynen, et al., 2008a;  Annola, et al., 2009). 
Furthermore, if placenta is collected from a mother with some disease or from a smoking 
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mother or one using drugs, the impact of these factors on the fetal exposure can be studied 
(Vähäkangas and Myllynen, 2006).  
Placental perfusion is a very tedious method and several criteria have been set to define 
for a successful perfusion. The leak of perfusate from fetal circulation to maternal 
circulation is probably the most serious problem encountered (Pienimaki et al., 1995). If 
there are ruptures in the membranes between mother and fetal circulation, then leak from 
the fetal to the maternal circulation increases. Thus, low leak (< 4 ml/h) is evidence for the 
good integrity of placental membranes. A passively diffusible reference compound, usually 
antipyrine, is used to confirm the overlap between fetal and maternal circulations, and to 
normalize differences between individual placentas. In addition to the antipyrine, also 
other passively diffusing compounds such as tritiated water (3H2O) (Challier et al., 1985) 
and paracellularly transferring compounds such as creatinine can be used as  reference 
compounds (Brownbill et al., 2000;  May et al., 2008;  Malek and Leiser, 2009). The transfer of 
oxygen (O2) has also been used as a marker of overlap of maternal and fetal circulations 
(Wier and Miller, 1985;  Mathiesen, et al., 2010). Compounds of high molecular weight such 
as FITC-dextran, can be used as negative controls as they should not cross an intact 
placental barrier (Mathiesen, et al., 2010). The consumption of oxygen and glucose, as well 
as production of hormones can be used as indicators of viable tissue. Placental oxygen and 
glucose consumption as well as lactate production provide evidence of the metabolic 
activity of placenta (Mathiesen, et al., 2010). The production of hormones and proteins such 
as human chorionic gonadotropin (hCG), human placental lactogen (hPL) and leptin can 
also be measured to evaluate tissue viability and functionality (Linnemann et al., 2000;  
Mathiesen, et al., 2010).  
Even though the placental perfusion is a good system to study placental transfer and 
related mechanisms, it has also its limitations. Although the conditions of perfusion are 
kept as close to physiological conditions as possible, the placenta lacks the influence of 
surrounding tissue and body and thus does not fully reflect the physiological situation 
(Mathiesen, et al., 2010). Usually term placentas are perfused and thus the results reflect 
exposure at late gestation. However, the most sensitive period for fetal development is 
during the early stages of gestation (Anderson, et al., 2000;  Rogers and Kavlock, 2008). The 
first term, especially first two months, is the time of organogenesis and thus exposure to 
harmful chemicals during this period may lead to serious birth defects such as death of the 
embryo and malformations. Since the barrier between maternal and fetal circulations 
become thinner (from 50 μm to 5 μm) towards the end of gestation (Benirschke, et al., 2006), 
it has been proposed that  harmful compounds may penetrate through the placental barrier 
more easily at term which may lead to the increased exposure of the fetus (Vähäkangas and 
Myllynen, 2006; Mathiesen, et al., 2010). Thus transfer through the perfused term placenta 
may reflect the worst case situation of exposure. Second and third terms are periods of 
continuous growth and development and thus the harmful effects of exposure later in 
gestation are mainly related to growth retardation and functional deficits. Additionally, 
perfused placenta can also only be kept alive for certain hours (longest perfusions being up 
to 48 hours) and thus only relatively short term effects can be studied. For example, 
xenobiotic toxicity to placenta may be apparent only after longer periods of exposure.  
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Table 6. Examples of food contaminants evaluated using human placental perfusion 
 
Food contaminant Concentration 
in perfusion 
Perfusion 
time (h) 
Transfer through  
human placenta 
References    
Acrylamide 1 μg/ml 0.5 Transfer through 
placenta. 
(Sorgel et al., 
2002) 
Acrylamide, 
Glycidamide 
5 or 10 μg/ml 4 Transfer similar to AP1.  
 
(Annola et al., 
2008) 
2-amino-3-
methylimidazo[4,5-
f]quinoline (IQ) 
0.5μM 4 Transfer similar to AP. 
Inhibition of ABCG2 had 
no effect on IQ transfer 
(Immonen et 
al., 2010) 
2-amino-1-methyl-6-
phenylimidazo[4,5-
b]pyridine (PhIP) 
 
2 μM 6 Transfer slower than that 
of AP. ABCG2 inhibitor 
KO143 increase transfer 
into fetal circulation. 
(Myllynen et 
al., 2008a) 
Benzo[α]pyrene (BP) 1 μM 6 Transfer slower than that 
of AP. Addition of 
albumin increases 
transfer. 
(Mathiesen et 
al., 2009;  
Karttunen et 
al., 2010) 
 
 0.1 and 1 μM 6 Transfer slower than that 
of AP. ABCB1 inhibitor 
verapamil did not affect 
transfer.  
(Karttunen, et 
al., 2010) 
Bisphenol A 10 ng/ml 3 Transfer similar to 
antipyrine. 
(Balakrishnan 
et al., 2010) 
Cadmium (Cd) 0, 10, 20, or 
100 nmol 
4 Transfer through 
placenta. Toxic effects to 
placenta. Cd decrease 
transfer of zinc to fetal 
circulation. 
(Wier et al., 
1990) 
 
 12 or 24 μg/ml 
(as CdCl2) 
5 Slow transfer. (Boadi et al., 
1991) 
Cadmium (Cd),  
Selenite (Se) 
Cd:20 nmol/ml   
Se: 2, 20 and 
40 nmol/ml 
4 Cd and Se transfer 
through placenta, 
equilibrates within 4 
hours. 
(Eisenmann 
and Miller, 
1994) 
Deoxynivalenol (DON) 100 ng/ml 4 Transfer slower than that 
of AP. 
(Nielsen et al., 
2011) 
 
Nitrosodimethylamine 
(NDMA) 
1 or 5 μM 4  / 6 Transfer similar to AP. 
 
(Annola et al., 
2009) 
Non-dioxin-like 
polychlorinated 
biphenyls (NDLPCBs): 
PCB180 and PCB52 
1.5 mM 
 
2.5 Transfer slower than that 
of AP. Transfer of 
PCB180 was quicker than 
that of PCB52. 
(Correia 
Carreira et al., 
2011) 
4-nonylphenol  30 ng/ml 3 Transfer slower than that 
of AP. 
(Balakrishnan 
et al., 2011) 
Parathion 1 μg/ml 2-4.5 Transfer slower than that 
of AP. 
(Benjaminov 
et al., 1992) 
Phthalates 10 and 25 μg/L 2.5 Slow or nonexisting 
transfer. Transfer slower 
than that of AP. 
(Mose et al., 
2007a;  Mose 
et al., 2007b) 
Polybrominated 
diphenyl ethers 
(PBDEs): BDE-47, 
BDE-99 and BDE-209 
1 ng/mL 4 Transfer slower than that 
of AP. BDE-47 and BDE-
99 go through the 
placenta.  
(Frederiksen 
et al., 2010) 
TCDD 6.0 pg/mL 6 Not transferred, 
accumulation to tissue. 
(Pedersen et 
al., 2010) 
1AP = antipyrine  
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2.2.4 In vitro studies 
Microsomal and cytosol preparations of human placenta can be utilized to study 
metabolism of xenobiotics in human placenta (Vähäkangas and Myllynen, 2006). Fractions 
can be prepared by centrifugation from placentas of different stages and thus used to 
address both early and late placental enzyme activities (Myren, et al., 2007). These studies 
also provide information about interindividual differences in the capability to metabolize 
xenobiotics (Vähäkangas and Myllynen, 2006). 
Placental plasma membrane vesicles isolated from membranes of brush border or basal 
surface of term syncytiotrophoblast have been used to study placental transport (Shennan, 
1988;  Boyd, 1991). By using this method it has been possible to study transport 
mechanisms from both the fetal and the maternal plasma membranes separately (Murer 
and Kinne, 1980). The disadvantage of this system is that membrane transporter activities 
are measured in the absence of regulatory factors and therefore do not truly reflect the in 
vivo situation (Myren, et al., 2007). Placental tissue can also be cultured as tissue explants in 
which the tissue integrity and structure is partially maintained (Vähäkangas and Myllynen, 
2006). Placental tissue can be collected from placentas at different stages of gestation and 
cultured for several days (Miller et al., 2005). However, the viability of tissue is restricted in 
tissue culture and tissue is not as well preserved as in the case with perfused tissue (Di 
Santo et al., 2003). Tissue explants can be used for a variety of purposes, such as studies of 
placental transport, metabolism, endocrine and enzyme function, cellular proliferation and 
differentiation (Miller, et al., 2005;  Myren, et al., 2007).  
Human trophoblast cell lines originating from normal tissue, malignant tissue or from 
embryonic carcinomas can be utilized to study placental functions (Vähäkangas and 
Myllynen, 2006;  Myren, et al., 2007). Primary cell lines prepared from normal tissue 
represent more closely placental tissue than cell lines originating from carcinomas. 
However, primary trophoblastic cell lines are difficult to culture and become easily 
contaminated by other cell types. For this reason, cell lines originating from 
choriocarcinoma are more commonly used. BeWo, JEG-3 and JAR are three main 
choriocarcinoma cell lines. The BeWo cell line is comprised of cytotrophoblasts with no 
differentiation to syncytia (Wadsack et al., 2003). The JEG-3 cell line is derived from BeWo 
cells; these cells form large multinucleated syncytia in culture. The JAR cell line resembles 
early placental trophoblasts and can differentiate into trophoblast like cells. 
The BeWo cell line, the monolayer-forming trophoblast cell line (Pattillo and Gey, 1968), 
is probably the most commonly used. This cell line is easy to maintain by passage and 
grows within a relatively short period of time (Bode et al., 2006). The BeWo cells display 
morphological properties and biochemical marker enzymes common to normal 
trophoblasts (van der Ende et al., 1990) and secretes placental hormones (human chorionic 
gonadotropin, progesterone, placental lactogen) (Pattillo and Gey, 1968;  Pattillo et al., 1979;  
Nickel and Cattini, 1991). Several cytokines such as IL6 and IL8 (Fujisawa et al., 2000), IFNα, 
IFNβ and IL10 (Bennett et al., 1996) are expressed in BeWo cells. There is also metabolic 
activity in BeWo cells, since activities of CYP 1A1 and 1A2 have been detected and are 
inducible in BeWo cells (Avery et al., 2003). BeWo cells are also known to express several 
transporters such as ABC transporters (Evseenko et al., 2006). ABCG2, ABCC1, ABCC3 and 
ABCC5 transporters have been detected at mRNA level and ABCG2 and ABCC1 in protein 
levels in BeWo cells (Pascolo et al., 2003;  Ceckova et al., 2006;  Evseenko, et al., 2006). No 
mRNA or minimal amount of mRNA of ABCB1 has been detected in BeWo cells (Ceckova, 
et al., 2006;  Mark and Waddell, 2006) However, the expression of transporters may be 
affected by the growth conditions of BeWo cells (Pascolo et al., 2001). Due to their useful 
characteristics, cells have been used to study transport functions in placenta. However, only 
BeWo b24 and b30 clones grow as a tight monolayer and are suitable for transporter studies 
in Transwell plates (Bode, et al., 2006). Recent study also indicates that JEG-3 cells grown in 
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special medium form tight layer and are suitable for placental transporter studies (Ikeda et 
al., 2011). 
2.3 PLACENTA: STRUCTURE AND FUNCTION IN RELATION TO THE 
SCOPE OF THE THESIS  
2.3.1  Placental structure 
The human placenta, an organ between mother and fetus, is a primary route for fetal 
exposure. The development of the placenta starts after 6 to 7 days of fertilization when the 
blastocyst embeds itself into the uterine wall (Benirschke, et al., 2006). The inner cell mass of 
blastocyst, called the embryoblast, develops into the embryo and the outer cell mass, 
trophoblast, develops into the placenta (Sadler, 2004). 
The trophoblast differentiates into two layers; the cytotrophoblast (an inner layer of 
mononucleated cells) and the syncytiotrophoblast (an outer multinucleated zone without 
distinct cell boundaries) (Sadler, 2004;  Benirschke, et al., 2006). Cytotrophoblasts further 
proliferate and differentiate into the syncytiotrophoblast which together form the placental 
primary villi. The formation of capillaries into villus form the intraembryonic circulatory 
system connecting placenta to the fetus. The further development of the villous capillary 
system leads to contact of capillaries with the chorionic plate and the connecting stalk 
(develops to umbilical cord), thus giving rise to the extraembryonic vascular system and 
contact with the circulation of the mother (Sadler, 2004).  
By the beginning of the fourth month, the placenta can be divided into maternal and 
fetal compartments (Figure 5) (Sadler, 2004;  Benirschke, et al., 2006). The maternal side of 
the placenta is bordered by the decidual plate and the fetal side by the chorionic plate. The 
space between these two plates is filled with intervillous lakes of maternal blood which are 
replaced 3 or 4 times per minute. Maternal blood enters the intervillous space through the 
narrow endometrial spiral arteries. Because of the high pressure, blood flows deep into 
intervillous space around villous trees which are thus bathed in maternal blood. The 
membrane between maternal and fetal blood is initially composed of four layers (the 
endothelial lining of fetal vessels, the connective tissue in the villus core, the 
cytotrophoblastic layer and the syncytiotrophoblast) but by the fourth month, 
cytotrophoblastic cells and some connective tissue cells of villus disappear. The 
syncytiotrophoblast and endothelial wall of the blood vessels are then the only layers that 
separate the maternal and fetal circulations, increasing the rate of exchange (Sadler, 2004;  
Benirschke, et al., 2006).  
As gestation advances, the placenta enlarges as a result of the continuous growth and the 
expansion of the uterus. At full term, the placenta is 20-25 cm in diameter and 2-2.5 cm 
thick and it typically weighs approximately 500 grams (Figure 6) (Sadler, 2004). The 
maternal (basal) surface of the placenta is connected to the wall of uterus and is subdivided 
into 10 to 40 slightly elevated areas called maternal cotyledons. The fetal (apical) surface of 
the placenta is covered by a number of large arteries and veins, the chorionic vessels, which 
converge toward the umbilical cord. The umbilical cord with two arteries and one vein 
connects placenta and fetus. 
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Figure 5. Schematic structure of human placenta. A) Structure of placental cotyledon B) 
Enlargement of placental barrier. Amount of cytotrophoblasts and connective tissue is reduced 
with advanging gestation. Modified from (Saunders, 2009). 
 
 
 
 
Figure 6. Full term placenta. A) Fetal surface of the placenta covered with arteries and veins, 
which converge towards the umbilical cord. B) Maternal surface of the placenta subdivided into 
cotyledons. 
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2.3.2 Functions 
The main functions of the placenta are to provide nutrients (amino acids, free fatty acids, 
carbohydrates and vitamins) for the developing fetus, exchange gases (oxygen, carbon 
dioxide and carbon monoxide) and remove waste products (Sadler, 2004;  Evans and 
Ganjam, 2011). The placenta produces also hormones which maintain pregnancy and are 
important for fetal development. Placental production of both progesterone and estrogen 
increases exponentially after the 6th week of pregnancy (Newbern and Freemark, 2011). 
During the first months of gestation, progesterone, the most important hormone for the 
maintenance of pregnancy, is produced by the corpus lustrum, but by the end of fourth 
month it is fully produced by the placenta. Progesterone stimulates maternal food intake 
and maintains pregnancy by preventing the maternal immune system from attacking the 
fetus which expresses paternal antigens (Druckmann and Druckmann, 2005;  Newbern and 
Freemark, 2011). Estrogenic hormones stimulate uterine growth by increasing 
uteroplacental blood flow and endometrial prostaglandin synthesis, enhances receptor 
mediated uptake of LDL cholesterol for steroid production and stimulates development of 
the mammary glands by increasing prolactin synthesis and secretion (Sadler, 2004;  
Newbern and Freemark, 2011). Human chorionic gonadotropin (hCG), hormone mainly 
produced in syncytiotrophoblast, promotes progesterone production of the ovarian corpus 
luteum cells at the beginning of gestation (Cole, 2010). hCG also promotes the fusion of 
cytotrophoblastic cells and their differentiation into syncytiotrophoblast as well as 
angiogenesis in the uterus during pregnancy. Since hCG is produced throughout the 
pregnancy, levels peaking at 10 weeks, its presence in urine or blood is used as an indicator 
of pregnancy. Placental growth hormone (PGH) and human placental lactogen (hPL) are 
also produced by the placental syncytiotrophoblast (Newbern and Freemark, 2011). PGH 
promotes fetal growth by regulating maternal insulin resistance and maternal nutrient 
stores and hPL also regulates insulin production. The expression of placental alkaline 
phosphatase (PLAP) in the cytotrophoblasts and syncytiotrophoblast increases steadily 
throughout pregnancy until term (Leitner et al., 2001;  Bellazi et al., 2010). The primary 
function of PLAP is unclear, but it has been postulated to regulate growth and promote 
remodeling of fetal tissues (She et al., 2000a;  She et al., 2000b). When gestation advances 
placenta starts to age and syncytial knots, aggregates of aging nuclei are formed (Jones and 
Fox, 1977). These knots are removed from the metabolically active areas of the 
syncytiotrophoblast and released into the maternal circulation.  Release of these 
microparticles, expressing PLAP or human leukocyte antigen G (HLA-G) is enhanced both 
with advancing gestation and during stressful conditions such as oxidative stress (Guller et 
al., 2011). 
2.3.3 Placental xenobiotic metabolism 
Most of the toxins require metabolic activation to elicit their toxic properties. The structural 
change of the molecule is catalyzed by metabolizing enzymes expressed throughout the 
body. Among human tissues, liver has the highest activity of metabolizing enzymes, but 
there is some level of metabolism in all tissues, including placenta. The CYP450 enzymes 
are the most important enzymes catalyzing functionalization (phase I) reactions 
(hydrolysis, reduction and oxidation). Conjugation (phase II) reactions (glucuronidation, 
sulfonation, acetylation, methylation, conjugation with glutathione and amino acids) are 
followed by functionalization and are catalyzed by sulfotransferases, 
glucuronyltransferases, N-acetyltransferases and glutathione-S-transferases (Myllynen et 
al., 2009).  
 The placenta contains low levels of CYP enzymes (mainly CYP1A1), reductases, and 
transferases with variation depending on the stage of placental development (Hakkola et 
al., 1996a;  Hakkola et al., 1996b;  Pasanen, 1999;  Pavek and Dvorak, 2008). CYP1A1 is active 
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in placenta throughout the gestation (Hakkola, et al., 1996a;  Hakkola, et al., 1996b;  Collier 
et al., 2002b) and it has also been reported to be involved in the bioactivation of 
benzo(a)pyrene (Vähäkangas et al., 1989) and 17ß-estradiol (Zhu et al., 2002). CYP1A2 has 
been detected at messenger RNA (mRNA) level in the placenta during the first trimester, 
although no functional activity has been detected during this time or in term placentas 
(Hakkola, et al., 1996a;  Hakkola, et al., 1996b;  Myllynen, et al., 2007). CYP2A and B are not 
detected in human placenta at any stages of gestation (Hakkola, et al., 1996a;  Hakkola, et al., 
1996b). CYP2E1 has been detected at mRNA and protein level in the first trimester and 
term placenta (Hakkola, et al., 1996a;  Hakkola, et al., 1996b;  Rasheed et al., 1997;  Collier, et 
al., 2002b). CYP3A4–7 enzymes have been detected both at mRNA and at protein levels in 
first trimester and term placentas, but these enzymes are not functionally active (Hakkola, 
et al., 1996a;  Hakkola, et al., 1996b;  Myllynen, et al., 2007).  
Placenta has also been reported to express some conjugating-enzymes like glutathione S-
transferase (GST), epoxide hydrolase (EH), N-acetyltransferase (NAT), sulfotransferases 
(SULT) and uridine 5ಿ-diphosphate-glucuronyltransferase (UGT) (Smelt et al., 2000;  Collier 
et al., 2002a;  Myllynen, et al., 2007). In human placenta GST is active from early pregnancy 
throughout gestation with the activity being linked more likely to hormone production 
than detoxication of xenobiotics (Pacifici and Rane, 1981;  Pasanen, 1999). EH develops 
during the first trimester of pregnancy and is detectable in the human placenta at weeks of 
8 to 9. UGTs are active throughout gestation and may be important in protecting fetus by 
detoxifying and eliminating endo- and xenobiotics (Collier, et al., 2002a;  Collier, et al., 
2002b).   
There are large interindividual differences in the expression levels of metabolizing 
enzymes in placenta. Placental metabolizing activities are also altered by maternal alcohol 
and drug abuse as well as tobacco smoking. For example, CYP1A expression and activity in 
placenta are increased by maternal smoking (Collier, et al., 2002b;  Suter et al., 2010) and 
alcohol consumption (Collier, et al., 2002b). Placental CYP2E1 levels are also induced in 
heavy drinkers (Rasheed, et al., 1997) and CYP19 (aromatase) activities by tobacco smoke 
(Pasanen and Pelkonen, 1990;  Hakkola et al., 1998). Placental activities of UGTs are also 
elevated in the placentas collected from mothers who smoke or both drink alcohol and 
smoke tobacco (Collier, et al., 2002a). In addition to lifestyle factors; also maternal 
medications may affect the metabolic enzyme expression and activity in placenta. For 
example, the anti-HIV drug 3-azido-3-deoxythymidine (AZT) has been reported to increase 
the activity of CYP1A, glucuronidases, CYP reductases and GST enzymes and decrease the 
activity of UGT enzymes in JEG-3 cell line and primary explants from term and first-
trimester placenta (Collier et al., 2003). 
2.3.4 Transfer mechanisms 
The exposure of pregnant mother to harmful compounds may lead to the exposure of fetus 
because most of the compounds cross placental barrier at least to some extent. Most of the 
compounds cross placenta by passive diffusion either by transcellular or paracellular routes 
(Lewis et al., 2011). Passive diffusion does not require energy i.e. molecules diffuse down a 
concentration gradient. Molecules which cannot diffuse through placenta can be transferred 
by mechanisms such as by facilitated diffusion and active transport, although phagocytosis 
and pinocytosis also occur (Myllynen, et al., 2007;  Evans and Ganjam, 2011). Facilitated 
diffusion is mediated by carrier molecules which move substances down the concentration 
gradient and this kind of transport does not require energy. Facilitated diffusion is 
suggested to be involved to the transfer of nutrients (e.g. glucose, fatty acids) and a few 
drugs [e.g. ganciclovir (used for treating cytomegalovirus infection), the antibiotic 
cephalexin and glucocorticoids] through the placental barrier (Syme et al., 2004;  Lewis, et 
al., 2011). Placenta contains tens of transporter proteins which can transfer both 
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endogenous (e.g. amino acids) and exogenous compounds (e.g. anticancer drugs) against 
an electrochemical or concentration gradient. Depending on the localization and function of 
the transporter, the molecules can be transferred either in the maternal or fetal directions 
(Myllynen, et al., 2007). Transfer mediated by transporters as well as phagocytosis and 
pinocytosis require energy. Phagocytosis and pinocytosis are slow mechanisms and do not 
play a significant role in the transfer of xenobiotics through the placenta. Phagocytosis is 
mainly involved in the tissue homeostasis but it also participates in the removal of 
pathogens (Bevilacqua et al., 2010). Pinosytosis is involved in the transfer of some proteins.  
The rate of transfer is determined by the properties of the compound, e.g. the size of the 
molecule, pKa, lipid solubility and protein binding (Myllynen, et al., 2007). Transfer is 
proportional to the size of transferred molecule and small (less than 500 Da), lipophilic 
molecules which are unionized and unbound to plasma proteins cross placenta most easily 
(Anger et al., 2011). Ionized compounds have poor lipid solubilities and thus do not 
permeate easily through biological membranes. The extent of ionization depends on the pH 
and properties of the compound (pKa). In the fetal circulation pH is slightly (difference ~0.1 
unit) lower than in maternal circulation. This may lead to ion trapping, when re-ionized 
basic compounds accumulate in fetal circulation (Vähäkangas and Myllynen, 2009). 
Only free compounds can cross the placenta and thus protein binding of a molecule can 
significantly affect the transfer rate of a molecule. Binding to plasma proteins increases the 
size of molecule and thus toxicants bound to proteins are not likely to cross membranes. 
However, the high concentration of proteins on the other side of the barrier may also 
increase transfer. To reach balance between both sides of the barrier, free molecules move 
towards the compartment with a high concentration of proteins which thus have smaller 
portion of free molecules. The concentrations of maternal and fetal albumin and α-1 acid 
glycoprotein (AAG) change during pregnancy, which influences the transplacental passage 
of foreign substances (Notarianni, 1990; Frederiksen, 2001). The physiological concentration 
of maternal albumin during late pregnancy declines to about 30 mg/ml which is 
approximately 25% lower than the non-pregnant value (Krauer et al., 1984;  Larsson et al., 
2008). The fetal albumin concentration is highest, approximately 20% greater than the 
maternal, during late gestation (Krauer, et al., 1984;  Hill and Abramson, 1988). The 
maternal AAG concentration decreases during pregnancy and is 30% lower at term 
(Notarianni, 1990). At term, fetal AAG plasma concentrations are 30-40 % of maternal 
concentrations (Hill and Abramson, 1988). The decline in the maternal albumin and AAG 
concentrations leads to an increase of the free fractions of xenobiotics in maternal blood 
(Myllynen, et al., 2007). This may lead to increased elimination of xenobiotics, but also to 
increased fetal exposure. Xenobiotics can also accumulate in placenta and be later released 
from placental tissue. 
2.3.5 Placental transporters 
The numbers of transporters are found in placental barrier, both in syncytiotrophoblast and 
fetal capillary endothelium. In the syncytiotrophoblast, transporters are located in both 
apical and basolateral membranes transferring compounds in and out of 
syncytiotrophoblast (Figure 7) (St-Pierre et al., 2000;  Kolwankar et al., 2005;  Evseenko, et al., 
2006). Depending on the nature of transporters, the concentration of substrates is either 
increased (uptake transporters) or decreased (efflux transporters) in the cells. Efflux 
transporters in the apical surface of syncytiotrophoblast pump substrates back to the 
maternal circulation and thus can putatively protect fetus from the exposure to xenobiotics. 
However, fetal exposure to toxins is determined by the net effect of different kind of 
transporters. Placenta is known to express at least several ABC transporters (ABCG2/BCRP, 
ABCB1/p-glycoprotein, ABCC1-5/MRP1-5), organic anion transporters (OATP8/SLC21A8, 
OATPA-E/SLC21A12, OAT4/SLC22A11), organic cation transporters (OCT3/SLC22A3, 
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OCTN1/SLC22A4, OCTN2/SLC22A5), 5-HT transporters and noradrenaline transporters 
(Vähäkangas and Myllynen, 2009). There is an overlap in the substrate specificities of 
transporters and the same compound may be transferred by several transporters 
(Myllynen, et al., 2007). Additionally, xenobiotics structurally similar to endogenous 
substrates can also be transported by nutrient transporters (Ramamoorthy et al., 1995;  
Uchino et al., 2002). Toxicologically, the most important transporters are the ABC efflux 
transporters. 
The transporters ABCB1, ABCC2 and ABCG2 are located predominantly in the apical 
surface of syncytiotrophoblast, pumping substrates back into the maternal circulation 
(Figure 7) (Vähäkangas and Myllynen, 2009). ABCC1, ABCC3 and ABCC5 are expressed in 
both the basolateral membrane of syncytiotrophoblast and capillary endothelium. The 
OAT4 transporter is also located on the basolateral surface of the syncytiotrophoblast, but 
due to its uptake function, it pumps substrates towards the maternal circulation. The 
expression of transporters varies depending on the stage of gestation. The expression of 
ABCB1 is highest at the early stages of gestation and then decreases as gestation advances 
(Mathias et al., 2005;  Sun et al., 2006). Thus it may have a significant role protecting the 
fetus during the first term which is the most sensitive period to fetus. ABCG2, the most 
abundant transporter in placenta, is expressing throughout the whole gestation. However, 
in human placenta, there is some contradictory data about ABCG2 expression levels, some 
suggesting no change in expression levels (mRNA and protein) during gestation (Mathias, 
et al., 2005), some pointing to an increase in protein levels towards the end of gestation 
(Yeboah et al., 2006) and some decreased levels (mRNA and protein) towards end of 
gestation (Meyer zu Schwabedissen et al., 2006). ABCC2 expression is increased towards 
end of gestation (Meyer zu Schwabedissen et al., 2005). The expression of these transporters 
is regulated by pregnancy related steroid hormones, like estrogens and progesterone, 
growth factors and cytokines (Evseenko et al., 2007;  Mao, 2008). Additionally, some 
environmental estrogenic chemicals such as the mycotoxin, zearalenone (Prouillac et al., 
2009) and the plastic component, bisphenol A (Jin and Audus, 2005) can modulate 
expression levels of ABC transporters. 
 
 
 
Figure 7. Localization of ABC transporters in human placenta. Modified from (Vähäkangas and 
Myllynen, 2009). 
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There is a wide range of compounds like drugs and natural compounds which are 
substrates for ABC transporters. The substrates of ABCB1 are usually organic molecules, 
size ranging 200 kD to 1900 kD, and most are usually hydrophobic, even though some are 
amphipathic in nature (Schinkel and Jonker, 2003). Many anticancer drugs, as well as 
natural compounds, are known substrate of ABCB1 (Schinkel and Jonker, 2003;  
Vähäkangas and Myllynen, 2009). The two mycotoxins, deoxynivalenol and nivalenol, are 
substrates of ABCB1 in Caco-2 and/or LLCPK1-MDR1 cells (Tep et al., 2007;  Videmann et 
al., 2007). The major difference between ABCB1 and ABCC transporters is that ABCC 
transporters (ABCC1-5) transfer also conjugated substrates (glutathione-, glucuronate- and 
sulfate-conjugates) in addition to the parent compounds (Schinkel and Jonker, 2003). While 
ABCC1 transfers mainly endogenous substrates rather than xenobiotics (Atkinson et al., 
2003), many heavy metals such as copper, cadmium and arsenic, are substrates of ABCC2 
(Leslie et al., 2005). The mycotoxin zearalenone and its metabolites are substrates for 
ABCC1, ABCC2 and/or ABCC3 in MDCK-MRP1, MDCK-MRP2 and/or MDCK-MRP3 cells 
(Videmann et al., 2009). Deoxynivalenol and nivalenol are also substrates for ABCC2 in 
MDCKII-MRP2 cells (Tep, et al., 2007;  Videmann, et al., 2007). ABCG2 substrate specificity 
seems to overlap with the other ABC transporters (Vähäkangas and Myllynen, 2009). 
Common food contaminants such as mycotoxins AFB1 (van Herwaarden et al., 2006) and 
OTA (Schrickx et al., 2006) have been shown to be substrates for ABCG2 in MDCK-II cells 
transduced with murine Bcrp1 and in Caco-2 cells, respectively. In MDCK-II cells 
heterocyclic amines 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (van 
Herwaarden et al., 2003), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) (van Herwaarden, 
et al., 2006) and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) (van Herwaarden, 
et al., 2006) were substrates for ABCG2.  
In animal studies, both ABCB1 (Lankas et al., 1998;  Smit et al., 1999;  Pavek et al., 2001) 
and ABCG2 (Jonker et al., 2000;  Staud et al., 2006;  Zhang et al., 2007;  Cygalova et al., 2008;  
Zhou et al., 2008) have been shown to limit transfer of substrates into fetal circulation. 
Studies using human placental perfusion method have also revealed that the transporters 
can influence the transfer of substrates through the human placenta. For example,  the 
ABCG2 transporter has limited the transfer of PhIP to fetal circulation during 6 hours of 
perfusion (Myllynen, et al., 2008a). On the other hand, ABCG2 did not have influence on 
transfer of IQ (Immonen, et al., 2010) and ABCB1 did not have change the transfer of BP 
(Karttunen, et al., 2010). In addition to food toxins, ABC transporters have been shown to 
limit the transfer of many drugs through the perfused human placenta (Molsa et al., 2005;  
May, et al., 2008;  Nanovskaya et al., 2008a;  Pollex et al., 2008). 
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3 Aims of the study 
Pregnant mothers are exposed to a wide variety of chemicals originating from food, drugs 
or from environmental sources. Most of the compounds cross the placental barrier and thus 
exposure of pregnant mother may lead to the exposure of the developing fetus. Even 
though transplacental transfer of drugs has been widely studied, there is still very limited 
information about the transplacental transfer of food contaminants and environmental 
chemicals. The mechanisms involved in placental transfer of xenobiotics are also poorly 
understood. 
Due to the underdeveloped defense mechanisms, exposure to the genotoxic or 
carcinogenic compounds may be extremely harmful to the rapidly growing fetus. Most of 
the chemicals require metabolic activation before they can elicit toxic properties. Even 
though the capability of xenobiotic metabolism in placenta is limited compared to liver, 
placenta is known to express many metabolic enzymes. However, there is only limited 
information about xenobiotic metabolism in human placenta.  
 
This thesis is a part of a larger research program (NewGeneris, the European Union's 6th 
Framework Programme) on fetal exposure and the potential toxicity of food and 
environmental chemicals. It is hypothesized that food contaminants and / or their 
metabolites cross the placental barrier at least to some extent either by passive diffusion or 
by active transfer mechanisms. Consequently, in order to address transplacental transfer 
and related mechanisms the thesis had three separate but complementary specific 
objectives as follows:  
 
 
1. To establish the transplacental transfer of aflatoxin B1, ochratoxin A and 
melamine using ex vivo human placental perfusion. 
 
 
2. To determine placental metabolism of aflatoxin B1 and ochratoxin A in the 
perfused human placenta ex vivo and/or in cellular fractions of human placenta in 
vitro. 
 
 
3. To characterize the role of placental transporters in the transfer of mycotoxins and 
melamine using cell lines expressing placental transporters and ex vivo human 
placental perfusion method. 
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4 Materials and methods 
4.1 EX VIVO HUMAN PLACENTAL PERFUSION METHOD (I, II, III) 
4.1.1 Ethical aspects 
In Finland, the human placenta is discarded after delivery and the use of the placenta for 
research purposes does not affect delivery or the treatment of the mother and child in any 
way. The Research Ethics Committee of the University Hospital District of Kuopio region 
has reviewed and approved this study (11.5.2005). Placentas were collected immediately 
after a normal delivery or a caesarean section from uncomplicated, fulltime pregnancies 
(37-42) of healthy, non-smoking mothers who delivered in Kuopio University Hospital.  
Biomedical research is regulated both by national legislation (Act of Medical Research 
9.4.1999/488) and international agreements such as the Declaration of Helsinki, the 
Universal Declaration of Bioethics and Human Rights and Good Clinical Practices. Ethical 
aspects were taken into account when recruiting study participants (Halkoaho et al., 2010). 
All participants were fully competent to give consent for their partipation. The mothers 
were informed about the study by a nurse and also written information was given before 
written consent was obtained. Placentas were anonymized for the study. 
4.1.2 Preparation of tissue and perfusion (I, II, III) 
In this study, human placentas were perfused using a dual recirculating perfusion method 
described earlier (Pienimaki, et al., 1995;  Annola, et al., 2008;  Myllynen, et al., 2008a). The 
details of the set up of the system (Figure 8), composition of perfusion medium, perfusions 
conditions (pH, temperature, flow rate, oxygen and carbon dioxide levels, pressure of 
perfusion system) and experimental flow (sampling, adjustment of conditions) are 
explained in publications I, II and III. 
In brief, placentas were collected within 10 minutes of birth and preperfusate with 
heparin was immediately injected into the umbilical cord vessels to prevent the formation 
of blood clots. In the perfusion laboratory, artery-vein pair of the peripheral cotyledon 
lobule of placenta was cannulated to form fetal circulation and placed into the perfusion 
apparatus (Figure 9). On the maternal side, two cannulas were inserted through the basal 
plate into the intervillous space of the placenta. The flow of the perfusate was intiated and 
perfusate was circulated separately in both maternal and fetal circulations. Before addition 
of the study and reference compounds, the placenta was allowed to recover from hypoxia 
for 30 minutes. Perfusion was carried out for predefined times (Table 7) and samples were 
collected from both circulations at designated time points. Perfused placental tissue and 
control samples from the same placenta were collected for tissue histology and other 
analytical procedures. The perfusions carried out in those studies are shown in the Table 7, 
the physicochemical properties of compounds in Table 8 and all methods used for the 
study in Table 9. 
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Figure 8. Placental perfusion system used in perfusion studies. A) Schematic figure of the 
perfusion system. B) Perfusion equipment used in the University of Eastern Finland. 
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Figure 9. Cannulated placenta in perfusion chamber. 
 
 
 
Table 7. Perfusions carried out in the study. Toxin concentration, perfusion time, number of 
perfusions, leak and glucose consumption in successful perfusions. 
 
Compound and 
concentrationa 
Perfusion 
time 
(hours) 
Number of 
successful 
perfusion/  
all perfusionsb 
(%) 
Mean 
leak 
ml/h 
Glucose 
consumption 
range 
μmol/h/g Publication 
AFB1 5 μM 2 4/15 (27) 2.8 23-59.7 I 
AFB1 0.5 μM 4 4/9 (44) 2.8 3.2-12.5 I 
OTA 1.7 nM 4-6 4/6 (67) 1.6 21.9-41.2 II 
OTA 1.7 nM + Ko143 4-6 4/6 (67) 2.0 14.3-85.4 II 
OTA 1.7 nM + Prob. 4-6 2/2 (100) 1.6 39.4-44.4 II 
OTA 2 μM 6 1/1 (100) 1.4 29.1 II 
OTA 0.7 μM 4 -20 2/2 (100) 0.8 7.6-20.3 II 
Melamine 1 mM 4 3/6 (50) 2.7 22.9-39.2 III 
Melamine 10 μM 4 4/8 (50) 1.0 25.5-47.4 III 
Melamine 10 μM + CYA  4 4/4  (100) 1.3 22.5-38.2 III 
aAbbreviations: AFB1 = aflatoxin B1, OTA = ochratoxin A, CYA = cyanuric acid 10 nM, Ko143 =ABCG2 
inhibitor 2 μM, Prob = Probenicid, ABCC2 inhibitor 5 μM 
bAll perfusions = perfusions in which the studied compound was added into the fetal circulation. 
 
 
 
Table 8. Physicochemical properties of aflatoxin B1 (AFB1), ochratoxin A (OTA) and melamine 
 
Chemical 
Molecular 
weight 
(g/mol) pKa 
Water 
solubility 
Protein 
binding References 
AFB1 312.3 NA Not soluble Binding to 
albumin 
(Fermentec;  
Grant and 
Phillips, 1998) 
OTA 403.8 Carboxyl group: 
4.2-4.4 
Phenolic moiety: 
7.0-7.3 
Limited 
solubility  
(~1 mg/ml) 
Binding to 
albumin 
(Perry et al., 
2003;  El Khoury 
and Atoui, 2010) 
Melamine 126.1 5.35 3.24 mg/ml NA (WHO, 2008) 
NA = no information available 
 
 
32 
 
 
4.1.3 Criteria for successful perfusion 
Strict criteria for valid perfusions were applied throughout the study. The most important 
criteria were a volume loss from the fetal to maternal circulation (leak) less than 4 ml/h  (3.3 
%) and transfer of the reference compound antipyrine with a feto/maternal ratio (FM ratio) 
above 0.75 (Pienimaki, et al., 1995;  Myllynen, et al., 2008a;  Mathiesen, et al., 2010). Blood 
gases (pO2 and pCO2) and pH were monitored and pH was adjusted to the physiological 
level when needed. Glucose consumption (Table 7) and hCG (Human Chorionic 
Gonadotropin) hormone production were also measured in all perfusions to evaluate the 
viability of placental tissue during perfusions. Additionally, release of PLAP (Placental 
alkaline phosphatase) was also measured in melamine perfusions (publication III) to 
evaluate possible toxicity of melamine and CYA. 
4.2 CELLULAR FRACTIONS OF HUMAN PLACENTA FOR METABOLISM 
STUDIES (I, III) 
To study whether there was metabolism of the mycotoxins AFB1 and OTA, placental tissue 
was collected and microsomal and cytosolic fractions were prepared as described in 
publication I. In brief, tissue was homogenized into buffer, and fractions of tissue were 
separated by centrifugation. Fractions were stored at -80 °C until used. Microsomal or 
cytosolic protein was incubated with a reaction mixture containing AFB1 or OTA as 
described in publications I and II. Samples were analyzed by HPLC to find out possible 
metabolites.  
4.3 CELL CULTURES 
4.3.1 BeWo cells (III, IV) 
The BeWo cell line was purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). BeWo cells are originated from placental choriocarcinoma. The BeWo 
b30 clone was donated from Professor Lisbeth Knudsen’s laboratory (University of 
Copenhagen, Copenhagen, Denmark) with permission from Professor Alan Schwartz and 
coworkers who originally developed the BeWo b30 clone in the 1980s (Correia Carreira, et 
al., 2011). Cells were grown as described in publications III and IV either in RPMI or 
DMEM. Cells were tested to be free from mycoplasma contamination by measuring the 
presence of mycoplasma enzymes using the mycoplasma detection kit (publication IV). 
4.3.2 MDCK cells (III, IV) 
Madin-Darby Canine Kidney (MDCK) -cell lines (MDCK-BCRP, MDCK-MDR1 and MDCK-
MRP2) were donated from the Netherlands Cancer Institute (NKI-AVL, Amsterdam, 
Netherlands). Each of these cell lines are transfected with the human gene of transporter 
protein; either ABCG2 (MDCK-BCRP), ABCB1 (MDCK-MDR1) or ABCC2 (MDCK-MRP2). 
Cells were grown as described in publications III and IV either in RPMI or DMEM. Cells 
were tested to be free from mycoplasma contamination by measuring the presence of 
mycoplasma enzymes using the mycoplasma detection kit (publication IV). 
4.3.3 MTT assay for cell viability (III) 
The MTT assay was carried out in BeWo cells to investigate whether melamine is cytotoxic 
to placental cells.  Briefly, cells were seeded one day before experiment and assay was 
carried out using a standard MTT protocol. The MTT assay is one of the most commonly 
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used colorimetric assays for the determination of cell viability. This assay is dependent on 
conversion of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) into 
purple formazan crystals by active mitochondria. The formazan crystals are then dissolved 
and quantified spectrophotometrically (Mosmann, 1983). The color intensity is directly 
proportional to the number of living, metabolically active cells (Mosmann, 1983). Thus, a 
higher absorbance would reflect higher cell viability, meaning a lower cytotoxicity.  
4.4 CELL CULTURE METHODS FOR CHARACTERIZATION OF 
TRANSPORTERS  
4.4.1 Accumulation assay (III, IV) 
Accumulation assays were carried out in BeWo or MDCK -cells to determine whether 
toxins (AFB1, AFL, OTA or melamine) were substrates for the ABC transporters (ABCB1, 
ABCC2 and/or ABCG2). Details of the experiments are described in publications II and IV. 
The method was adapted and modified from the protocol published earlier (Bode, et al., 
2006). The assay measures the accumulation of studied compound within the cells. A 
higher accumulation in cells with inhibitor compared to control cells indicates that the 
inhibition of the transporter had affected the accumulation of studied compound and thus 
the compound is a substrate of the transporter. 
4.4.2 Inhibition assay (IV) 
Since fumitremorgin C (FTC), an inhibitor of ABCG2, is also a mycotoxin, it was of interest 
to study potential inhibition by AFB1, AFL and OTA on ABCG2. Since the MDCK-BCRP 
cell line expresses a higher amount of ABCG2 than BeWo cells, the assay was conducted in 
the MDCK-BCRP cell line. The potential inhibition of the accumulation of a known specific 
substrate of ABCG2, pheophorbide A (PhA), by AFB1, AFL or OTA was studied to 
determine whether these mycotoxins could modulate the function of the ABCG2 
transporter. Details of the experimental method are explained in publication IV and the 
method has been modified from the protocol of MDR1 Efflux assay kit (Millipore, MA, 
USA). In principle, cells were incubated in the presence of a fluorescent substrate and 
potential inhibitor compound (mycotoxin) to study whether the compound would affect 
the accumulation of the substrate. If accumulation was increased, then this was interpreted 
to mean that the studied compound inhibited the function of transporter. 
4.4.3 Transwell experiments (II) 
To investigate the influence of the protein concentration on the transfer of OTA, 
experiments on Transwell plates were carried out. BeWo b30 cells were seeded onto the 
Transwell filters and grown for 4-6 days until a confluent monolayer was achieved. 
Transepithelial electrical resistance (TEER) was measured to monitor the integrity of the 
monolayer before the assays. Details of the assay are described in publication III. The 
method was adapted and modified from the protocol published earlier (Bode, et al., 2006). 
In brief, OTA was added into the apical (upper) compartment and transfer to the 
basolateral (lower) compartment was monitored. The influence of different concentrations 
of human albumin on the transfer of OTA was evaluated.   
4.4.4 Transporter expression in cell lines (IV) 
The expression of ABC transporters was investigated in BeWo and MDCK –cell lines. The 
expression of transporter mRNA was studied by RT-PCR and protein expression by 
immunoblotting as described in publication IV. 
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4.5 ANALYSIS OF SAMPLES 
4.5.1 HPLC (I, II, III, IV) 
HPLC was used to analyze AFB1, OTA and their metabolites from perfusate or incubation 
solutions of placental fractions or cell culture experiments. Details of the analysis methods 
and sample preparation can be found in publications I, II and IV. The reference compound 
antipyrine was also analyzed by HPLC and details of the method are described in 
publications I, II and III. 
4.5.2 LC-MS (III) 
LC-MS was used to analyze melamine from perfusate and cell culture samples. Details of 
the method are explained in publication III. 
4.5.3 Scintillation counting (I, II) 
In this study, 3H-labelled toxins were used in both perfusions and Transwell cell culture 
experiments. Details of the sample preparation and analysis methods are described in 
publications I and II. In the analysis, the samples were mixed with scintillation liquid which 
absorbs the energy emitted by radioisotopes and re-emits it as flashes of light, which can be 
measured. 
4.5.4 Histological evaluation of perfused placental tissue (I, II, III) 
The histology of perfused placental tissue was evaluated from all successful perfusions. 
Placental tissue samples before and after perfusions were collected for the analysis. 
Hematoxylin-eosin staining was used to evaluate the cellular morphology. Hematoxylin-
eosin staining is the best known and most widely used staining procedure, which uses 
hematoxylin solution for nuclear staining and eosin solution for cytoplasmic staining. The 
preparation of samples is described in publications I, II and III. Possible crystal formation of 
melamine was analyzed from perfusions with melamine and melamine and CYA using Oil 
Red O staining to visualize possible crystals as described in publication III.  
4.6 STATISTICAL ANALYSIS 
All statistical calculations were performed using Graph Pad Prism 5 as described in 
publications I-IV. Paired Student’s t-test, one-way ANOVA with Tukey’s multiple 
comparison tests and two-way ANOVA with Bonferroni post hoc test were the main tests 
used for the data analysis. Data are presented as mean ± standard deviation (SD). P-value < 
0.05 was considered to be statistically significant. Perfusions n = 1 - 4; in vitro incubations n 
= 3 (3 sets of experiments with three replicates); cell culture experiments n = 3, (3 sets of 
experiments with three to six replicates).  
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Table 9. Methods used in this study 
 
Model Parameter analyzed Analytical method Publication 
Human placental 
perfusion 
Concentration of studied 
compound in perfusate or in 
placental tissue 
 
HPLC 
LC-MS 
Scintillation counting 
I, II, III 
 Concentration of AFB1 and OTA 
metabolites in perfusate 
 
HPLC I 
 Tissue and DNA binding of 
AFB1 
 
Scintillation counting I 
 
 Histology of tissue Staining 
Checking with microscope 
 
I, II, III 
 hCG ELISA I, II, III 
    
 PLAP ELISA III 
    
Placental microsomal 
and cytosolic fractions 
Concentration of AFB1 and OTA 
metabolites in incubation 
solution 
 
HPLC I, II 
Cell lines Expression of transporters in 
cell lines 
 
Immunoblotting 
RT-PCR 
IV 
Accumulation assay in 
BeWo and /or MDCK-
BCRP cell lines 
 
Concentration of studied 
compound accumulated in cells 
HPLC 
LC-MS  
 
III, IV 
Inhibition assay in 
MDCK-BCRP cells 
 
Concentration of fluorescence 
substrate accumulated in cells 
Fluorescence plate reader 
 
IV 
Monolayer of BeWo 
b30 cells in Transwell 
system 
 
Concentration of OTA passing 
through cell layer 
Scintillation counting II 
MTT assay Cell viability Spectrophotometer III 
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5 Results 
5.1 TRANSPLACENTAL TRANSFER OF AFLATOXIN B1, OCHRATOXIN A 
AND MELAMINE (I, II, III) 
All of the studied food contaminants were detectable in the fetal circulation, in some 
samples already at 5 minutes and in all samples by 30 minutes. Even though all of the 
studied compounds crossed the placenta at least to some extent, there were significant 
differences in transfer rates between these food contaminants. An increasing amount of 
AFB1 was detected in fetal circulation up to two hours. Subsequently, the, amount of AFB1 
remained stable or slightly decreased in fetal circulation, even though the amount of AFB1 
was still declining in the maternal circulation. This was clearly due to the metabolism of 
AFB1 to AFL which was found in both circulations. On the contrary, OTA was barely 
detectable in fetal circulation and fetal concentrations remained low even in a long 20-hour 
perfusion. Melamine concentrations gradually decreased in the maternal circulation and 
increased in fetal circulation over time. None of the studied compounds crossed the 
placenta as quickly as the passively diffusing antipyrine and did not reach equilibrium 
during the perfusions. When comparing the feto-maternal ratios (FM ratios) at 4 hours, 
significant differences were found between the compounds. The FM ratios of AFB1, OTA 
and melamine were 0.62±0.13, 0.02±0.007 and 0.64±0.18, respectively (Figure 10). One 
especially conspicuous finding was the extremely poor FM ratio of OTA which revealed 
almost no transfer of OTA through the perfused human placenta.  
All of the studied compounds were perfused with at least two concentrations (Table 7); 
AFB1 at concentrations of 5 μM or 0.5 μM, OTA at 2 μM, 1.7 nM or 0.7 nM and melamine at 
1 mM or 10 μM. There were no significant differences in the FM ratios between the 
concentrations of any of the studied compounds, indicating that the transfer was not 
concentration dependent. Melamine was also perfused with CYA to determine whether 
CYA would affect the transfer of melamine. The presence of CYA in the perfusion medium 
did not have any significant influence on the transfer of melamine. The influence of 
albumin on the transfer of OTA was also investigated in both BeWo cells and perfused 
placenta. The presence of albumin clearly had an influence on transfer of OTA, but there 
were no difference in OTA transfer at different albumin concentrations.  
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Figure 10. Comparison of feto-maternal ratios (FM ratios) of A) antipyrine and B) studied food 
contaminants in human placental perfusion. A) A mean ± SD of FM ratios of antipyrine in 
perfusions with aflatoxin B1 (AFB1), ochratoxin A (OTA) and melamine. B) FM ratio of AFB1, 
OTA and melamine in all perfusions with AFB1 (n = 8), OTA (n= 14) and melamine (n= 11). 
 
 
The passively diffusing chemical, antipyrine, was used as a reference compound to confirm 
the overlap of the fetal and maternal cotyledons and to compare results between 
perfusions. Antipyrine was detected in the fetal circulation already at 5 minutes after 
addition to the maternal circulation. The concentrations of antipyrine remained statistically 
significantly higher in maternal circulation up to 2 hours (Figure 11). Transfer of antipyrine 
was very similar with all of the studied compounds suggesting that all perfusions were 
comparable to each other with low variability being observed (Figure 10). The FM ratio of 
antipyrine ≥ 0.75 was regarded to indicate an acceptable perfusion. The FM ratios of 
antipyrine in AFB1, OTA and melamine perfusions were 1.03±0.06, 0.87±0.18 and 0.96±0.12, 
respectively, at 4 hours. 
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Figure 11. Transfer of antipyrine (AP) through perfused human placenta. Graph represents 
transfer of antipyrine up to 4 hours in all successful perfusions (leak from fetal to maternal 
circulation < 4ml/h; FM ratio of AP at 4 hours ≥ 0.75) with aflatoxin B1, ochratoxin A and 
melamine (n = 29), ***p<0.001. 
 
 
Perfusions were accepted for the analysis only when the leak from fetal circulation to 
maternal circulation was less than 4 ml/h (3.3 %). When comparing the leak between 
different perfusions, the highest mean of leak was in perfusions with AFB1 (2.8 ml/h) and 1 
mM melamine (2.7 ml/h) (Table 7). When comparing the mean of leaks between the 
different concentrations of toxin, there seemed to be a tendency for a higher leak with 
higher concentrations of toxin. In all acceptable perfusions, placental tissue consumed 
glucose, consumption ranging from 3.2 to 59.6 μmol/h/g (Table 7), and produced hCG 
indicating that the tissues were viable. The increase in the PLAP concentrations in 
perfusions with melamine and CYA indicated that the combination was more toxic than 
melamine on its own. However, the structure of placental tissue was well preserved in all 
perfusions when monitored by histochemistry. 
5.2 PLACENTAL METABOLISM OF AFLATOXIN B1 AND OCHRATOXIN A 
(I, II) 
Placental metabolism of mycotoxins, AFB1 and OTA, were studied in perfused placenta as 
well as in in vitro incubations with placental microsomes and cytosol. AFB1 was 
metabolized to the hydroxylated metabolite, aflatoxicol (AFL) while OTA was not 
metabolized in human placenta.  
AFL was detected from perfusion samples in both maternal and fetal circulations as well 
as in cytosolic fraction in in vitro incubations (Figure 12). A small amount of AFL was also 
detected in microsomal incubations (Figure 5, publication I), but this was probably due to 
contamination of cytosolic enzymes in the microsomal fractions. No metabolites other than 
AFL were detected in perfusions or incubations. In perfused placenta, approximately 10 % 
of 5 μM AFB1 was converted to AFL during 2 hours and when placenta was perfused with 
0.5 μM AFB1 for 4 hours about 15% of AFB1 was converted into AFL (Figure 12A). AFL 
accumulated into fetal circulation and after 30 minutes the concentration of AFL was higher 
in fetal circulation than in maternal circulation. In the in vitro incubations, the formation of 
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AFL was proportional to time and approximately 30 % of added AFB1 was converted to 
AFL during the 2 hours of incubation with placental cytosol (Figure 12B). Incubations with 
cytosolic and microsomal protein from eight different placentas revealed extensive 
variations in the formation of AFL pointing to differences in placental metabolic activity 
between different placentas (Figure 5, publication I). The formation of AFL between 
placentas varied from 3.2 % to 22.6% with 5 μM AFB1 and from 3.6 % to 24.6 % with 0.5 μM 
AFB1 in incubations with placental cytosol. AFB1 was metabolized to AFL also in BeWo 
cells (publication IV). 
 
 
 
Figure 12. Formation of aflatoxicol (AFL) A) in placental perfusion and B) in in vitro incubations 
with placental cytosolic fractions. A) Perfusions with 5 μM aflatoxin B1 (AFB1) were carried out 
for 2 hours (n = 4) and perfusions with 0.5 μM AFB1 for 4 hours (n = 4) B) In vitro incubations 
were done with 5 μM AFB1 (n = 3, triplicate samples of 3 different placentas were analyzed). 
 
5.3 ROLE OF TRANSPORTERS IN THE TRANSPLACENTAL TRANSFER OF 
MYCOTOXINS AND MELAMINE (III, IV) 
The expressions of ABCG2, ABCB1/4 and ABCC2 transporters were studied in the cell lines 
BeWo, MDCK-BCRP, MDCK-MDR1 and MDCK-MRP2 both at mRNA and protein level to 
compare levels of transporters between cell lines. As expected, ABCG2 was expressing only 
in BeWo and MDCK-BCRP cell line, ABCB1/4 in MDCK-MDR1 and ABCC2 in MDCK-
MRP2 cell line both at mRNA and protein level (Figure 13). Although in most of the 
analysis of BeWo cells, ABCG2 was the only transporter protein present, although in some 
of the analysis very low levels of ABCB1/4 and ABCC2 protein were detected in BeWo cells. 
Since BeWo cells did express very low or non-existent levels of any of the studied 
transporters other than ABCG2, they were used to study ABCG2, and MDCK cell lines 
expressing one transporter per cell line were used to screen for the other two transporters.  
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Figure 13. Expression of ABC transporters in different cell lines. Expression of A) ABCG2, B) 
ABCB1/4 and C) ABCC2 at mRNA (upper part, studied by RT-PCR) and protein level (lower part, 
immunoblotting) in cell lines BeWo, MDCK-MDR1, MDCK-MRP2 and MDCK-BCRP. 
 
 
The contribution of the placental transporters to the transfer of AFB1, AFL, OTA and 
melamine was investigated. The accumulation assay in BeWo and/or MDCK cells 
expressing one ABC transporter per cell line was carried out to determine whether these 
compounds would be substrates of placental transporters ABCB1, ABCC2 and/or ABCG2.   
The results from the accumulation assay showed that accumulation of OTA was 
significantly (p < 0.05) increased by fumitremorgin C (FTC), a specific inhibitor of ABCG2, 
proving that OTA is a substrate of ABCG2 (Figure 1, publication IV). As compared to 
control, the accumulation of OTA was increased 4.4 fold in BeWo cells and 2.9 fold in 
MDCK-BCRP cells. The accumulations of AFB1 and AFL were increased 1.6 and 1.1 fold in 
both BeWo cells and MDCK-BCRP cells. However, this increase was not statistically 
significant indicating that these aflatoxins may not be substrates of ABCG2. Interestingly, 
even though very similar, 1.6 and 1.1 fold increases were observed in both cell lines, 
significantly higher concentrations of mycotoxins accumulated in BeWo cells (Table 1, 
publication IV). The results from melamine accumulation assay in MDCK cells indicated 
that melamine was not a substrate for ABCB1, ABCC2 or ABCG2 transporters (Figure 4, 
publication III). 
The influence of ABCG2, ABCC2 and OAT4 transporters on the transfer of OTA in 
perfused placenta was also investigated. As seen from Figure 1 in publication II, OTA was 
poorly transferred through the perfused human term placenta. The inhibitors of ABCG2, 
ABCC2 and OAT4 transporters did not significantly increase the transfer of OTA through 
the placenta (Figure 2, publication II), indicating that these transporters did not have 
biologically significant influence on the transfer of OTA. 
 
 
 
 
41 
 
 
6 Discussion 
6.1 TRANSPLACENTAL TRANSFER OF AFLATOXIN B1, OCHRATOXIN A 
AND MELAMINE (I, II, III) 
6.1.1 Transfer of food contaminants through the perfused human placenta 
Since AFB1 and OTA are common food contaminants and melamine has been intentionally 
added into food, the pregnant mother may be exposed daily to these agents. If one wishes 
to assess the risk of fetal exposure to these harmful compounds, one needs to evaluate their 
transfer through the placenta. The transfer of AFB1, OTA and melamine through the 
perfused human placenta suggest that fetus is also exposed to these food contaminants if 
the mother is exposed via food or from other sources (publications I – III). This is in line 
with epidemiological and animal studies of these compounds. Both AFB1 and OTA have 
been detected in maternal blood, cord blood and blood of the infants (Denning, et al., 1990;  
Wild, et al., 1991;  Hsieh and Hsieh, 1993b;  Zimmerli and Dick, 1995;  Rosner, et al., 2000;  
Abdulrazzaq, et al., 2002;  Postupolski, et al., 2006;  Turner, et al., 2007). In humans, higher 
levels of OTA have been found in the fetal circulation than in the maternal circulation 
(Zimmerli and Dick, 1995;  Postupolski, et al., 2006;  Biasucci, et al., 2011) but in perfusions 
only minimal amount of OTA was transferred through the perfused placenta (publication 
II). There exists no previous information about transfer of melamine through human 
placenta but in animal studies, melamine has been shown to cross rat placenta (Chu, et al., 
2010;  Jingbin, et al., 2010;  Chan, et al., 2011) which is in line with perfusion studies. There is 
data indicating that possible exposure can occur to these food contaminants at both pre- 
and postnatal stages. 
Even though all of the studied compounds crossed placenta at least to some extent, there 
were significant differences observed between the compounds. Similarly to AFB1 and 
melamine, most of the xenobiotics studied so far cross placenta relatively easily and 
concentrations of xenobiotics increase in fetal circulation with time (Annola, et al., 2008;  
Myllynen, et al., 2008a;  Annola, et al., 2009;  Immonen, et al., 2010;  Karttunen, et al., 2010). 
However, there are also compounds that do not cross placenta (TCDD, EPO) (Schneider 
and Malek, 1995;  Pedersen, et al., 2010) or transfer is minimal (phthalates) (Mose, et al., 
2007a;  Mose, et al., 2007b). In a recent study, transfers of thirteen compounds, including 
AFB1 data (publication I), have been compared to the transfer of reference compound 
antipyrine in perfused placenta (Mose et al., 2012). Some of the compounds are able to cross 
placenta as well as the reference compound antipyrine, others only minimally. Based on the 
transfer rates, the compounds have been divided into groups which seem to be well 
correlated to their lipophilicity. The transfer of AFB1 occurs at a medium rate compared to 
other twelve compounds. 
Small (less than 500 Da), lipophilic compounds usually cross placenta easily by passive 
diffusion and equilibrate during the perfusion (Syme, et al., 2004;  Myllynen, et al., 2007;  
Anger, et al., 2011). Although both AFB1 (312.2 g/mol) and melamine (126.12 g/mol) are 
quite small compounds they did not equilibrate during the 4-hour perfusions indicating 
that mechanisms other than passive diffusion may be contributing to the transfer. 
Concentrations of OTA were almost non-existent in the fetal circulation and the transfer 
was significantly different compared to the other studied compounds. OTA is larger (403.8 
g/mol) than other two studied compounds but smaller than 500 Da, which is thought to be 
the limit for compounds to be able to cross placenta (Syme, et al., 2004). Thus, the molecular 
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size should not be a restricting factor for OTA transfer. In addition to OTA, there are also 
some other compounds that cross the placental barrier very slowly and their concentrations 
are barely detectable in the fetal circulation. In a recent study on phthalates, very low or 
even non-detectable levels of phthalates were found in fetal circulation (Mose, et al., 2007a;  
Mose, et al., 2007b) which is comparable to the transfer of OTA. Both of these xenobiotics 
are ionized at pH 7.4, which may partly explain their poor transfer through human 
placenta.  
Since only free compounds can cross membranes, both degree of ionization and extent of 
binding to plasma proteins can affect transfer of compounds. Earlier studies on placental 
perfusion have shown that protein binding has an influence on the transfer of compounds 
through the placenta (Nanovskaya et al., 2006;  Nanovskaya et al., 2008b;  Mathiesen, et al., 
2009;  Nanovskaya et al., 2009). The transfer of benzo(a)pyrene and the antidiabetic drug, 
rosiglitazone, increased when albumin concentrations were elevated to the normal 
physiological concentrations (Nanovskaya, et al., 2008b;  Mathiesen, et al., 2009). On the 
contrary, transfer of another antidiabetic drug, glyburide decreased due to the addition of 
albumin (Nanovskaya, et al., 2008b). OTA is known to bind to proteins, especially albumin 
(Chu, 1971;  Chu, 1974;  Hagelberg et al., 1989) and thus it was important to study the 
influence of albumin on the transfer of OTA. The results from Transwell system clearly 
indicated that the presence of albumin, irrespective of its concentration, decreased the 
transfer of OTA through cell layer (publication II). In perfused placenta transfer of OTA 
was minimal at both used protein concentrations. In addition to the degree of ionization, 
protein binding may be an important factor accounting for the poor transfer of OTA.  
Since placenta is a barrier between maternal and fetal circulations, xenobiotics can also 
accumulate in placenta. Usually compounds with high lipophilicities are more likely to 
accumulate in placental tissue (Ala-Kokko et al., 1995). In the literature some food 
contaminants, such as cadmium, have been reported to accumulate in human placenta in 
vivo (Kippler et al., 2010). In perfused placenta the highly lipophilic TCDD was accumulated 
into tissue (Pedersen, et al., 2010). Of the studied compounds, neither AFB1 nor melamine 
significantly accumulated in perfused human placenta, but 6 to 25% of OTA was found to 
accumulate in placental tissue. In addition to OTA, another mycotoxin, deoxynivalenol 
(DON) also significantly (17 ± 6 % of added DON) accumulated in perfused placental tissue 
(Nielsen, et al., 2011). Even though these mycotoxins accumulated to some extent into 
placental tissue, the properties of compounds differ quite extensively i.e. OTA is lipophilic 
(log Kow 4.74) (Garcia-Fonseca et al., 2008) and DON hydrophilic (log Kow -1.47) (NIH, 2009). 
Gold nanoparticles (10 to 30 nm) coated with polyethylene glycol (PEG) have also been 
reported to accumulate into perfused placental tissue because they are too large to cross the 
placental barrier (Myllynen et al., 2008b). 
Since OTA and AFB1 are highly toxic and carcinogenic (IARC, 2002), exposure to these 
agents poses a serious health risk for the developing fetus. Early exposure to AFB1 has been 
linked to a higher incidence of HCC at a young age, altered immune responses and growth 
impairment in humans (IARC, 2003;  Turner, et al., 2003). Additionally, both AFB1 and OTA 
are teratogenic in experimental animals (IARC, 2002). It is not yet known what kind of 
effects are caused by prenatal exposure to melamine. However, the recent data revealing 
the serious renal toxicity (WHO, 2009) and indications of altered immune responses in 
exposed infants and children  (Zhou, et al., 2010) as well as impaired learning and memory 
functions in infant rats (Yang, et al., 2011) hint that melamine is more harmful than 
previously believed. 
Rapidly developing fetus is very sensitive and the time of the exposure is critical for fetal 
development (Anderson, et al., 2000). Due to the changes in placenta during gestation, the 
transfer of xenobiotics probably differs at different stages of gestation. The barrier between 
maternal and fetal circulations becomes thin (from 50 μm to 5 μm) towards the end of 
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gestation and thus transfer may be easier at term (Benirschke, et al., 2006). Additionally, the 
expression of transporters also varies at different stages of gestation (Vähäkangas and 
Myllynen, 2009). Since only term placentas were used in placental perfusions, these present 
results reflect exposure at term. This may partly explain the contradictory results on OTA 
transfer between the in vivo epidemiological and ex vivo perfusion studies. The high levels 
of OTA in fetal serum detected previously in vivo (Zimmerli and Dick, 1995;  Postupolski, et 
al., 2006) may be due to accumulation in the early stages of gestation. Based on the 
perfusions conducted here, there does not seem to be significant transfer of OTA at term. 
Transfer of OTA at mid gestation and limited transfer in late gestation has been reported 
also in mouse (Appelgren and Arora, 1983). Since transfer may be different at different 
stages of gestation, it would be useful to perfuse placentas also from earlier stages of 
gestation.  
6.1.2 Challenges of perfusions 
Ethical questions need to be taken into account when human tissue such as placenta is 
collected for research purposes. In Finland, placenta is discarded after delivery and thus the 
use of placenta for research does not cause any risk to mother or fetus. The donation of the 
placenta needs to be voluntary and sufficient information about the study needs to be 
given. Halkoaho and coworkers (2010) have studied the ethical aspects of placental 
perfusion. They interviewed mothers donating placenta for perfusions, as well as the 
midwives and researchers carrying out perfusion studies (Halkoaho, et al., 2010;  Halkoaho 
et al., 2011a;  Halkoaho et al., 2011b). Some of the mothers interviewed by Halkoaho had 
donated placenta for the studies carried out for this thesis (publications I – III). Halkoaho’s 
results (2010) revealed that the mothers were willing to donate placenta for placental 
perfusion if they felt that the study was important. Due to the stressful situation, it is 
important to pay special attention to the way that information was provided. Also in a 
Danish study by Lind and coworkers, it was revealed that mothers were willing to donate 
placenta for perfusion studies (Lind et al., 2007). The mothers giving their placentas for this 
study (publications I - III) were informed by midwives and written informed consent was 
collected from all participating mothers and placentas were anonymized in the study. In 
the opinion of the midwives there were no ethical problems to use placenta for research but 
they felt that the situation of asking permission for study was not optimal and hurried 
because of the many tasks required to ensure a safe birth (Halkoaho, et al., 2011b). Thus the 
consent requirement should not be sought during the medical procedures. In Halkoaho’s 
study (2011a) researchers highlighted that the good communication between mothers, 
midwives and researchers was very important in the recruiting process. 
Placental perfusion is a very demanding and tedious method with many factors affecting 
its success rate (Vähäkangas and Myllynen, 2006). First, it was important to collect placenta 
soon after birth. Thus good cooperation with midwives was important in collecting 
placentas. Since only placentas in good condition can be perfused, placentas were checked 
carefully for signs of trauma. The selection of veins and arteriae from peripheral area for 
cannulation was also critical as the maternal and fetal circulations need to be matched to 
ensure the transfer of compounds. The conditions of the perfusion, such as the composition 
of the perfusate, its pH and temperature all affect the success of perfusion (Mathiesen, et al., 
2010) and were monitored and adjusted to physiological levels. However, it is difficult to 
truly mimic physiological conditions since there are numerous proteins and endogenous 
factors in blood (Mathiesen, et al., 2010).  
To guarantee the quality of the study, strict criteria were set before perfusions were 
accepted. The perfusion technique as well as criteria for acceptable perfusions vary between 
laboratories (Mathiesen, et al., 2010). An acceptable small leak from fetal to maternal 
circulation has been shown to be a good indicator of successful perfusion (Pienimaki, et al., 
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1995). Thus here, the increase in the leak was the first indicator of a failing perfusion. What 
is viewed as an acceptable leak varies between laboratories usually from 2 to 4 ml/h 
(Mathiesen, et al., 2010) but even higher leaks have been described in the literature (up to 10 
ml/h) (Wier, et al., 1990). In this study, only perfusions with a leak less than 4 ml/h were 
accepted instead of 3 ml/h which is usually used as the criterion in our laboratory (Annola, 
et al., 2008;  Karttunen, et al., 2010). However this criterion seemed to be difficult to achieve 
with the toxic AFB1 and a compromise had to be made.  
   The passively diffusing reference compound antipyrine is widely used to confirm the 
necessary overlap between fetal and maternal circulations, and to normalize differences 
between different placentas and perfusions (Benjaminov, et al., 1992;  Ala-Kokko, et al., 
1995;  Vähäkangas and Myllynen, 2006;  Myllynen, et al., 2008b;  Annola, et al., 2009;  
Balakrishnan, et al., 2010;  Karttunen, et al., 2010;  Balakrishnan, et al., 2011). The kinetics of 
the antipyrine in placenta are well known and since it diffuses passively through the 
placenta it has been proposed to be a suitable reference compound for flow limited 
compounds (Mathiesen, et al., 2010). Generally the FM ratio of antipyrine should be above 
0.75 (Mathiesen, et al., 2010) and this criterion was also used in the current study. The 
transfer of antipyrine was very similar in all successful perfusions, suggesting that the 
perfusions with different compounds were comparable to each other.  
The consumptions of oxygen and glucose as well as the production of lactate and 
placental hormones can be monitored to evaluate viability of the tissue (Vähäkangas and 
Myllynen, 2006;  Mathiesen, et al., 2010). Placental hormone production is the most sensitive 
of these markers for viability. In this study, glucose consumption and production of hCG 
were analyzed. All successful perfusions consumed glucose and produced hCG. However, 
in perfusions with higher concentrations of AFB1 or melamine, combination of melamine 
and CYA as well as in the OTA perfusion with inhibitors, hCG production was lower 
/declined towards the end of perfusions, indicative of a decrease in the tissue viability. In 
melamine perfusions, release of PLAP was also analyzed and used as an indicator of tissue 
damage. Syncytiotrophoplastic microparticles expressing PLAP or human leukocyte 
antigen G (HLA-G) detach from the placenta even during normal pregnancy and this is 
enhanced during stressful conditions like pre-eclampsia (Guller, et al., 2011). Thus 
microparticles released by apoptotic functions can be used as biomarkers of pathogenic 
pregnancies (e.g. pre-eclampsia) and restricted fetal development (Orozco et al., 2009) as 
well as an indicator of tissue damage of perfused placental tissue (Di Santo et al., 2007;  
Malek et al., 2009). Microparticles released during perfusions have also been shown to 
contain plasminogen activator inhibitors (PAIs) and endoglin (Eng) elevated levels of 
which are linked to placental damage and endothelial dysfunction in pre-eclampsia (Guller, 
et al., 2011). In the melamine study (publication III), concentrations of PLAP increased 
towards the end of the perfusions with the increase being most obvious in perfusions with 
both melamine and CYA, indicating that this combination was more toxic than melamine 
on its own. The combination of melamine and CYA was also found to be more toxic in 
BeWo cell cultures which is in line with the perfusion results.  Histological examination of 
placenta can be used as an additional quality control of perfusions (Myllynen, et al., 2008b;  
Mathiesen, et al., 2010). Analysis of histology showed that the structure of placental villi 
was well preserved in all perfusions indicating good survival of the tissue (publications I – 
III). 
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6.2 METABOLISM OF MYCOTOXINS IN HUMAN PLACENTA 
The results from this study clearly showed that AFB1 could be metabolized to AFL in both 
perfused placenta and in in vitro incubations with placental tissue fractions (publication I). 
The formation of AFL is mediated by NADPH dependent reductases (Wong and Hsieh, 
1976;  Salhab and Edwards, 1977) which are known to be expressed also in placenta 
(Myllynen, et al., 2007). Since AFL is as toxic as AFB1 itself, the formation of AFL does not, 
however, protect the fetus from the toxicity of AFB1 (Bailey, et al., 1994;  Bailey, et al., 1998). 
AFL also accumulates in the fetal circulation and can be converted back to AFB1 in placenta 
or fetus. In this study AFL was the only metabolite detected.  
In liver CYP1A2 and CYP3A4 are the main enzymes metabolizing AFB1. Since these 
enzymes are not active in term placenta, it is not surprising that no metabolites other than 
AFL were detected either in perfused placenta or in the in vitro incubations. However, one 
earlier study has reported epoxidation of AFB1 by lipoxygenase purified from the human 
term placenta and from the intrauterine conceptual tissue (Datta and Kulkarni, 1994). The 
increase of mutagenic activity of AFB1 in Salmonella typhimurium TA100 by placental 
microsomal protein is another indication of the capacity of placental tissue to activate AFB1 
(Sawada, et al., 1993). 
Metabolism of OTA was also studied in in vitro incubations. Although OTA is 
metabolized to 4-(R)-OH-OTA also by CYP 1A1 (Wu, et al., 2011), which is active and 
inducible in term placenta, neither this nor any other metabolites were detected, indicating 
that the term placenta is not capable of metabolizing OTA. OTA is metabolized to several 
metabolites in many tissues in both animals and humans as well as by fungi, yeast and 
bacteria (Wu, et al., 2011), but there is no previous information available about OTA 
metabolism in placenta.  
Because of its limited enzymatic activity, placenta has a low capability to convert 
xenobiotics to the less toxic and more easily secreted form. However, there is a large 
interindividual variation in the enzymatic activities of placenta as reflected in the variation 
of AFL formation between placentas. Additionally, placental metabolic enzymatic activities 
are altered by lifestyle factors, such as smoking and alcohol, as well as by the use of drugs 
(Pasanen et al., 1990;  Hakkola, et al., 1996a;  Collier, et al., 2002a;  Collier, et al., 2002b;  Suter, 
et al., 2010) and these are factors which may influence metabolism of xenobiotics in 
placental tissue. 
6.3 ROLE OF TRANSPORTERS IN THE TRANSFER OF FOOD 
CONTAMINANTS 
Neither OTA, nor AFB1 or melamine equilibrated during perfusions, indicating that 
transporters could be limiting the transfer of these compounds. Earlier studies have shown 
that OTA is a substrate for ABCG2 and ABCC2 in Caco-2 (Schrickx, et al., 2006) and to 
OAT4 in S2 cells (mouse proximal tubule cells transfected with the gene for the transporter) 
(Jung et al., 2001;  Babu et al., 2002). AFB1 is a substrate to ABCG2 in MDCK-II cells 
transduced with the murine Bcrp1 (van Herwaarden, et al., 2006). However, in this study 
(publication IV) only OTA was a clear substrate for ABCG2. Even though OTA has been 
earlier reported to be substrate for ABCG2, ABCC2 and OAT4 (Jung, et al., 2001;  Babu, et 
al., 2002;  Schrickx, et al., 2006), and role of ABCG2 was confirmed in both BeWo and 
MDCK-BCRP cell lines in this study (publication IV), none of these transporters influenced 
the transfer of OTA in perfused human placenta. For example, inhibition of these 
transporters did not significantly influence the transfer of OTA (publication II), indicating 
that these transporters do not have biological significance in transplacental transfer of OTA. 
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With respect to AFB1, which has been earlier reported to be an ABCG2 substrate (van 
Herwaarden, et al., 2006), accumulation of AFB1 was increased in the presence of the 
specific inhibitor of ABCG2 in this study (publication IV), although the increase was quite 
small and not statistically significant. In the study of van Herwaarden (2006) cells were 
transfected with the murine gene of ABCG2, not the human gene. Differences between 
species may also explain the differences in the results. Thus, further experiments will be 
needed to prove significance of ABCG2 in the transfer of AFB1. 
There are similar results about the contribution of transporters to the transfer of IQ. It 
has been reported to be a substrate of ABCG2 (van Herwaarden, et al., 2006) but in placental 
perfusion, inhibition of ABCG2 did not influence the transfer of IQ in the study by 
Immonen and coworkers (2010). The contradictory results may be due to differences 
between in vitro and ex vivo models. While placental perfusion retains the structure and 
function of the placenta, cell models lack the influence of surrounding cells and tissue 
(Poulsen et al., 2009). Placenta also expresses numerous transporters and thus other 
transporters may have a more significant role in the transfer of these chemicals.  
In this study only the role of some ABC transporters was investigated but as stated 
placenta expresses numerous transporters and the role of the other transporters should not 
be ignored (Vähäkangas and Myllynen, 2009). Xenobiotics can be substrates for many 
transporters and thus the transfer of a xenobiotic through placenta is determined by the net 
effect of all transporters. Xenobiotics structurally similar to endogenous substrates can also 
be carried by transporters usually transferring endogenous substrates such as nutrients 
(Ganapathy et al., 2000) and this can affect the transfer of essential nutrients. Additionally, 
the expression of the different transporters varies at different stages of gestation (Mathias, 
et al., 2005;  Sun, et al., 2006); (Yeboah, et al., 2006); (Meyer zu Schwabedissen, et al., 2006) as 
well as due to the influence of xenobiotics (Jin and Audus, 2005;  Prouillac, et al., 2009). 
Additionally, there are interindividual variations in the expression and activity of 
transporters (see review (Ni and Mao, 2011). Due to genetic polymorphism, subjects from 
different ethnic groups may exhibit differences in the transporters in placenta. For example, 
single nucleotide polymorphism (SNP) of C421A, common in Chinese and Japanese 
popolations, has been reported to be associated with a lower expression of ABCG2 protein 
in placental tissue. There are also indications that some SNPs are associated with lower 
levels of ABCB1 in placenta (Ni and Mao, 2011). Since the efflux transporters putatively 
protect the fetus from xenobiotic exposure, genetic variability of transporters may modify 
the sensitivity to xenobiotics and partly explain different fetal outcomes. Thus, the 
involvement of the transporters in the transplacental transfer of xenobiotics needs to be 
studied also in placentas from the early stages of gestation and from different ethnic groups 
as well as utilizing complementary experimental models in order to obtain a more realistic 
perspective of the transplacental transfer of xenobiotics. 
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6.4 FUTURE PROSPECTIVES 
Information about transplacental transfer as well as the mechanisms involved in this 
process are needed to evaluate fetal exposure and to assess fetal risk for xenobiotic 
exposure. Due to the differences between species, human data is most useful for fetal risk 
assessment. Thus the human placental perfusion method which retains the structure and 
function of human placenta is a good model for studying transplacental transfer and 
related mechanisms of xenobiotics. There are numerous transporters in placenta and 
further studies are needed to clarify the role of these transporters in the transplacental 
transfer of xenobiotics.  
Since placenta is an important organ for fetal development and the maintenance of 
pregnancy, any toxic agents damaging placenta may be also harmful for the developing 
fetus. For example there are indications that xenobiotic exposure may alter gene expression 
in the placenta and is thus probably linked to the development of diseases later in life. In 
addition to mutations, epigenetic modifications may be linked to xenobiotic exposures 
during the fetal period and susceptibility to diseases later in life. Thus, in addition to 
transfer studies, it would be also important to clarify the toxic influences of xenobiotics and 
mechanisms of toxicity in the placenta. 
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7 Summary and Conclusions 
Disasters such as fetal exposure to thalidomide and diethylstilbestrol have shown that 
exposure of fetus to harmful compounds can have serious concequences not only to the 
developing fetus but perhaps also to future generations. Because of the increasing 
incidences of diseases such as cancers at young age, concern about the fetal exposure to 
environmental agents have been raised. Not only genetic factors, but also fetal and 
childhood environment including the nutritional status and xenobiotic exposure are 
believed to be critical for the fetal growth and lifelong disease risk. However, even though 
the pregnant mother may be exposed to harmful contaminants on a  daily basis through her 
diet or from other sources, there is only a limited amount of data about the fetal exposure to 
environmental and food toxins.  
This study provided new information about the transplacental transfer and metabolism 
of food contaminants aflatoxin B1 (AFB1), ochratoxin A (OTA) and melamine. The results 
of the study confirmed that these compounds can cross perfused human term placenta at 
least to some extent. Thus exposure of a pregnant mother to these food contaminants may 
lead to the exposure of developing fetus. Since these contaminants are toxic to human, 
exposure may pose a risk to the fetus.  
 
 
More specifically: 
  
1. AFB1 and melamine were detected in the fetal circulation of perfused human 
term placenta and were easily transferred through the placenta. On the contrary, 
OTA concentrations in fetal circulation remained extremely low, indicating poor 
transfer through the placenta. There were thus significant differences in the 
transfer rates of these three food contaminants. Transfer of these compounds also 
significantly differed from the passively diffusing reference compound 
antipyrine indicating that mechanisms other than passive diffusion contribute to 
the transfer. The results from the perfusion experiments were in line with 
epidemiological and animal studies and thus ex vivo human placental perfusion 
which retains the structure of human placenta seems to be a good method for 
studying transplacental transfer of food contaminants. Since term placenta was 
used, the results reflect exposure at the end of gestation. 
 
2. AFB1 was metabolized to the hydroxylated metabolite aflatoxicol (AFL) in both 
perfused human placenta and in in vitro incubations with placental cytosol. AFL 
was the only metabolite detected in either of these experimental models. In 
perfused placenta, AFL accumulated in fetal circulation. Since AFL is as toxic as 
AFB1, the formation of AFL does not protect the fetus from the toxicity of AFB1. 
No metabolites of OTA were detected in either perfused human placenta or 
during in vitro incubations with placental cytosol or microsomes indicating that 
OTA is not metabolized in human placenta. Results from both perfusion and in 
vitro incubations were very similar indicating that these methods are comparable 
to each other both reflecting in their own way placental xenobiotic metabolism.   
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3. In vitro studies in trophoblastic cells, originating from human choriocarcinoma 
(BeWo cells), and in canine kidney cells expressing the gene of the human 
ABCG2 transporter (MDCK-BCRP cells) confirmed that OTA is a substrate for the 
ABCG2 transporter, in cells relevant to human placenta. However, none of the 
transporters ABCG2, ABCC2 or OAT4 alone influenced the transfer of OTA 
through perfused human placenta indicating that these transporters do not have 
a biologically significant role in the transfer of OTA.  
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Various toxic substances may be 
present in food, but fetal exposure 
to food contaminants is poorly 
understood. This study provided new 
information about the transplacental 
transfer and metabolism of the food 
contaminants aflatoxin B1 (AFB1), 
ochratoxin A (OTA) and melamine. 
This study confirmed that these 
compounds can cross perfused 
human term placenta, at least to some 
extent. Thus exposure of a pregnant 
mother to these food contaminants 
may also lead to the exposure of 
the developing fetus. Since these 
contaminants are toxic to humans, 
exposure may pose a health risk to 
the developing fetus.
